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Foram objetivos deste estudo: 1) comparar o efeito das formulações (gel e 
comprimido) de metronidazol (Mtz) sobre o debridamento periodontal (DP) em pacientes 
fumantes; 2) comparar as concentrações plasmáticas (CP) e salivares (CS) destas 
formulações; 3) determinar a farmacocinética do Mtz em comprimido; e 4) avaliar o efeito 
do fumo na biodisponibilidade do Mtz comprimido. Cada objetivo constituiu um capítulo 
do estudo. Capítulo 1: 30 fumantes com periodontite crônica foram aleatoriamente 
divididos em 3 grupos: DP associado com 3 g de gel placebo; DP associado com aplicação 
tópica diária de 3 g de gel de benzoato de Mtz e; DP associado com dose oral única diária 
de 750 mg de Mtz (Flagyl®). Foram avaliados: Índice de Placa (IP), Índice de Sangramento 
Gengival (ISG), Profundidade à Sondagem (PS) e Nível Clínico de Inserção relativo (NIC); 
nos tempos: pré-operatório, baseline, e após 30, 90 e 180 dias do tratamento periodontal. 
Nenhuma diferença significante foi observada entre os grupos para todos os parâmetros e 
tempos avaliados. Houve uma significante redução no ISG, PS e NIC em todos os tempos 
comparados ao baseline (p<0,05). Capítulo 2: 13 voluntários sadios receberam 
aleatoriamente dose oral única de 750mg de Mtz ou 3g de gel Mtz (15%). Amostras de 
plasma e saliva foram colhidas em diferentes tempos após administração. Cromatografia 
Líquida de Alta Eficiência (CLAE) foi usada para quantificar as CP e CS do Mtz. Os 
parâmetros farmacocinéticos concentração máxima (Cmax), área sob a curva de zero ao 
infinito (ASC0-inf), área sob a curva de zero a t (ASC0-t), volume de distribuição (VD) e 
clearence renal (CL) foram determinados. As CP do Mtz foram maiores que as CS nos 
períodos de 6 a 24 horas para o comprimido (p<0,05). Os parâmetros ASC0-inf e ASC0-t 
foram maiores no plasma que na saliva (p<0,05). As concentrações plasmáticas e salivares 
foram similares para a formulação gel (p>0,05). Capítulo 3: 13 fumantes (F) e 13 não-
fumantes (NF) receberam dose oral única de 750mg Mtz. Amostras de plasma e saliva 
foram colhidas em diferentes tempos após administração. A CLAE foi usada para 
quantificar as CP e CS do Mtz. Os parâmetros farmacocinéticos AUC, Cmax, Tmax, VD e CL 
foram determinados. Foram observadas redução significante nas concentrações plasmáticas 
no grupo F comparada ao NF em 1, 1,5 e 2 horas após a administração e na Cmax plasmática 




parâmetros farmacocinéticos do Mtz em saliva (p>0,05). Conclusão geral: 1) Não houve 
vantagem clínica no uso do Mtz associado ao DP; 2) A formulação em gel produziu igual 
disponibilidade de Mtz no plasma e na saliva; 3) Alguns dos parâmetros farmacocinéticos 
do Mtz foram maiores no plasma que na saliva para o comprimido; 4) O fumo interferiu 
apenas na biodisponibilidade plasmática do Mtz. 
 
Palavras-chave: periodontite crônica, metronidazol, fumantes, farmacocinética, avaliação 






 The aim of this study were 1) to compare the effect of metronidazole (Mtz) gel and 
tablet on debridement periodontal (DP) in smokers; 2) to compare Mtz gel and tablet 
concentrations in both blood plasma and saliva; 3) to determine the pharmacokinetic profile 
of Mtz tablet; and 4) to verify the effect of cigarette smoking on bioavailability of Mtz 
tablet. This study was divided in three chapters. Chapter 1: 30 patients smokers with 
chronic periodontitis were randomly assigned into 3 groups: PD combined with 3 g placebo 
gel; PD combined with daily topical application of 3 g  Mtz benzoate gel (15%); and PD 
combined with a daily single dose of 750 mg Mtz (Flagyl®). Clinical parameters evaluated 
were visible plaque index (VPI), gingival bleeding index (GBI), probing pocket depth 
(PPD) and relative attachment level (RAL) which were assessed preoperatively, baseline, 
and after 1, 3 and 6 months after PD. No significant difference was observed among the 
groups, considering all parameters tested (p>0.05). In all groups was observed a significant 
reduction in GBI, PPD and RAL, at all times compared to baseline (p<0.05). Chapter 2: 13 
volunteers randomly received 750 mg single oral dose FLagyl® and 3 g Mtz benzoate gel 
(15%). Blood and saliva samples were collected in different times after gel application and 
oral administration of Mtz. High-performance liquid chromatography (HPLC) was used to 
quantify plasmatic (PC) and salivary (SC) concentrations of Mtz. Pharmacokinetic 
parameters determined were: the highest concentration (Cmax), the time at which Cmax 
ocurred (Tmax), the area under concentration-time curve from zero to infinity (AUC0-∞), the 
area under concentration-time curve from zero to t (AUC0-t), distribution volume (VD) and 
renal clearance (CL). Plasma showed higher Mtz concentration from 6 to 24 hours after 
drug administration and the highest values concerning Tmax, AUC0-48h and AUC0-∞ than 
those obtained in saliva (p<0.05).  No significant difference was observed between SC and 
PC for Mtz gel considering all periods tested (p>0.05). Chapter 3: 13 smokers (S) and 13 
non-smokers (NS) received a single oral dose of 750 mg Mtz tablet. Blood and saliva 
samples were collected in different times after oral administration of Mtz. HPLC was used 
to quantify plasmatic and salivary Mtz concentrations. Pharmacokinetic parameters (ASC, 
Cmax, Tmax, VD and CL) were determined. A significant reduction in plasmatic Mtz 




and in Cmax to plasma (p<0.05). No significant difference was observed in Mtz 
concentration and pharmacokinetic parameters in saliva (p>0.05). Conclusions: 1) Mtz did 
not improve the clinical outcomes provided by PD alone; 2) Gel and tablet formulations 
had similar Mtz bioavailability in plasma and saliva; 3) Some pharmacokinetic parameters 
were higher in plasma than in saliva concerning Mtz tablet. 4) Smoking interfered with the 
plasmatic Mtz bioavailability but not the salivary.  
 
Key words: chronic periodontitis, metronidazole, smokers, pharmacokinetic, clinical 
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   A etiologia da doença periodontal envolve principalmente dois fatores: um 
hospedeiro susceptível e a presença de bactérias patogênicas. O processo da doença se 
desenvolve quando há uma quebra do equilíbrio existente entre resposta do hospedeiro e o 
desafio microbiano (Quirynen et al., 2001).  
Os microrganismos que causam a periodontite são capazes de agir diretamente 
no tecido periodontal ou de modificar a resposta do hospedeiro (Liebana et al., 2004). Três 
importantes passos têm sido definidos na patogênese da doença periodontal: 1) início do 
processo inflamatório por um biofilme microbiano; 2) resposta imuno-inflamatória ao 
biofilme e seus produtos e; 3) destruição do tecido conjuntivo e osso que constituem o 
periodonto (Novak et al., 2008).  
  A estrutura dental é uma superfície sólida adequada para a colonização de um 
grande grupo de bactérias patogênicas e não-patogênicas. A doença periodontal é sítio-
dependente e deixa uma gravação histórica do dano ocorrido no periodonto na forma de 
perda de inserção e de osso alveolar. O aumento na profundidade de sondagem e no número 
de sítios comprometidos indica tendência à perda de inserção subseqüente (Socransky & 
Haffajee, 1997).  
   O tratamento periodontal consiste na remoção do biofilme dental e do cálculo 
dental da superfície radicular, promovendo um quadro aceito como saúde periodontal, 
obtido por meio da adesão epitelial sobre a superfície radicular (Waerhaug, 1978; Mullally 
et al., 2008). 
 Na terapia periodontal convencional, a instrumentação mecânica é realizada por 
sextantes ou quadrantes em intervalos de 1 a 2 semanas, de maneira que o tratamento é 
concluído dentro de 4 a 6 semanas (Koshy et al., 2005). A raspagem e o alisamento 
radicular (RAR) são mecanismos eficazes no tratamento da doença periodontal, entretanto, 
em alguns casos, não é capaz de devolver ou manter a saúde periodontal, o que pode ser 
explicado pela recolonização de microrganismos em áreas já tratadas (Drisko, 1998). Os 






re-infecção das bolsas periodontais e explicar, em alguns casos, a resposta insignificante da 
terapia antibacteriana (Wong et al., 1999). 
  A desinfecção da boca toda em estágio único consiste na instrumentação 
mecânica em duas sessões dentro de 24 horas e aplicação de clorexidina em todos os nichos 
interbucais (Quirynen et al., 2001). A vantagem deste tratamento está na prevenção da 
recolonização de áreas já tratadas e na redução, em curto período de tempo e de maneira 
eficiente, da quantidade de bactérias subgengivais e em outros nichos intrabucais (Quirynen 
et al., 1995; Quirynen et al., 1999; Mongardini et al., 1999). 
  Jervoe-Storm et al. (2006) não observaram diferenças entre o tratamento 
convencional e a desinfecção de boca toda sem o uso da clorexidina (2 sessões de 2 horas 
cada, dentro de um período de 24 horas). Kosh et al. (2005) verificaram que a redução no 
tempo da instrumentação da boca toda com ultra-som (sessão única de 2 horas) não 
apresentava prejuízos nos resultados clínicos comparados à terapia convencional. Estes 
estudos contribuíram para dar suporte a uma nova abordagem da terapia periodontal não-
cirúrgica, o debridamento da superfície radicular. 
  O debridamento periodontal é uma instrumentação radicular leve, mais 
conservadora, feita em tempo reduzido. Não tem o objetivo de remover todo cálculo e 
cemento “contaminado” como na RAR, mas tornar a superfície radicular biocompatível 
para restabelecimento da inserção (Smart et al., 1990). 
  Os trabalhos de Wennstrom et al. (2001), Wennstrom et al. (2005) e Zanatta et 
al. (2006) não observaram diferenças clínicas quando comparados os procedimentos de 
debridamento periodontal em sessão única (duração de no máximo 1 hora) e RAR, o que 
permitiu sugerir que a instrumentação subgengival simplificada é efetiva no tratamento da 
periodontite crônica. 
   Os agentes antimicrobianos administrados por via sistêmica ou tópica podem 
aumentar a erradicação dos patógenos subgengivais (Jorgensen & Slots, 2000). A terapia 
antimicrobiana visa reforçar o tratamento periodontal mecânico e dar suporte às defesas do 
hospedeiro, inibindo os microrganismos que permanecem após a terapia convencional.  
   Devido à dificuldade dos procedimentos em eliminar completamente os 






recomendado como adjunto ao tratamento dos diferentes tipos de doença periodontal (Slots 
et al., 1990; Hitzig et al., 1994; Leiknes et al., 2007). A instrumentação ainda trata a 
doença periodontal de maneira inespecífica e pode falhar em eliminar periodontopatógenos 
como Actinomyces actinomycetemcomitans e Tanarella forsythia (Darby et al., 2001). 
Estes microrganismos podem escapar do tratamento mecânico devido à sua habilidade em 
invadir os tecidos periodontais ou residirem em estruturas dentais inacessíveis à 
instrumentação, como bolsas profundas e áreas de bifurcação (Rudney et al., 2001).  
  A organização em biofilmes permite que as bactérias sejam menos susceptíveis 
aos antimicrobianos (Anwar et al., 1992), o que poderia enfatizar a necessidade de associar 
a terapia mecânica periodontal ao uso dos antimicrobianos. Os agentes antimicrobianos 
podem ser mais efetivos quando o biofilme dental é inicialmente rompido pelo 
procedimento mecânico, expondo os patógenos periodontais a estas substâncias (Mullally 
et al., 2007). 
O uso dos agentes antimicrobianos por via sistêmica ou tópica como adjunto a 
terapia mecânica pode proporcionar benefícios ao tratamento periodontal em algumas 
situações específicas como na periodontite agressiva, na pobre resposta clínica à terapia 
mecânica, na doença sistêmica que possa afetar a resistência do hospedeiro (Greenstein et 
al., 2000; Jorgensen et al., 2005).  
Dentre os principais antimicrobianos utilizados no tratamento da periodontite 
estão o metronidazol (Mtz), as tetraciclinas e a combinação de amoxicilina/Mtz, sendo que 
esta associação vem sendo utilizada devido o surgimento de cepas de A. 
actinomycetemcomitans resistentes à tetraciclina (Mullally et al., 2007).  
 O Mtz, antimicrobiano do grupo dos nitroimidazóis, tem ação bactericida por 
interferir com a síntese do DNA bacteriano. É efetivo contra protozoários e anaeróbios 
gram-positivos e gram-negativos estritos. É completa e rapidamente absorvido por via oral 
atravessando barreiras teciduais em altas concentrações, as quais similares ou levemente 
menores àquelas encontradas no sangue (Spénard et al., 2004). Possui meia-vida de 
eliminação de aproximadamente 8,5 horas e clearence renal de 1,3 mL/min/kg. É excretado 
na urina após metabolismo hepático, sendo que apenas 10% da dose absorvida é excretada 






 Os efeitos colaterais ocorrem raramente e dificilmente são graves demais para 
causar descontinuidade da terapia (Lau et al., 1992). Os mais comuns são: dor de cabeça, 
náusea, xerostomia, gosto metálico, vômitos, diarréia e dor abdominal. Seu uso em 
pacientes com doenças neurológicas é desaconselhável devido à possível neurotoxicidade. 
Embora possa ser utilizado em gestantes durante todos os estágios da gestação sem nenhum 
efeito adverso aparente, o uso no primeiro trimestre não é aconselhável. Um monitoramento 
mais cuidadoso deve ser feito em pacientes com doenças hepáticas, alcoólatras ou que 
fazem uso concomitante com outras drogas que tenham metabolismo essencialmente 
hepático. 
 Embora muitos trabalhos tenham demonstrado benefício clínico adicional do 
Mtz quando adjunto a terapia mecânica no tratamento da doença periodontal (Lopez & 
Gamonal, 1998; Griffiths et al., 2000; López et al., 2000; Pavia et al., 2004; Carvalho et 
al., 2005; Moeintaghavi et al., 2007; Novak et al., 2008; Haffajee et al., 2008), pouca 
atenção tem sido dada à dose ou à duração do tratamento, gerando dúvidas quanto à 
posologia ideal deste agente. Elter et al. (1997) mostraram alguns estudos empregando Mtz, 
nos quais pôde ser observada a variabilidade na duração do tratamento (entre um e 14 dias) 
e na dose total (entre 2 e 33,6 g).  
 A chave para o entendimento da relação antimicrobiano-hospedeiro-bactéria 
reside no conhecimento de como as propriedades farmacocinéticas e dinâmicas podem 
afetar a posologia e o uso clínico dos fármacos. Uma vez que a efetividade de um agente 
antimicrobiano depende da sua concentração e permanência no sítio de ação, é importante 
correlacionar a concentração do Mtz com sua eficácia terapêutica, com a finalidade de 
estabelecer a melhor dosagem para o tratamento odontológico (Jansson, 2006). 
É conhecido que os fumantes têm maior risco em desenvolver a doença 
periodontal que os não-fumantes (Thomson et al., 2007) e normalmente respondem menos 
favoravelmente ao tratamento periodontal (Heasman et al. 2006; Johnson & Guthmiller, 
2007). Isto ocorre uma vez que o fumo, particularmente o cigarro, provoca alterações na 
resposta imuno-inflamatória do tecido do hospedeiro e na microvascularização gengival, 
supressão da função dos fibroblastos e osteoblastos, redução do conteúdo mineral ósseo e 






pacientes (Rosa et al., 2008). Os metabólitos do cigarro em doses elevadas prejudicam a 
fagocitose e alteram o padrão de liberação das enzimas neutrofílicas e em baixas 
concentrações estimulam a quimiotaxia de neutrófilos. Tais alterações da função 
neutrofílica resultam em prejuízos no controle da infecção periodontal e/ou danos aos 
tecidos periodontais adjacentes já que são fortemente associados à atividade de reabsorção 
óssea (Salvi et al., 1997).  
 Um dos objetivos do presente estudo foi verificar o efeito do Mtz, nas formulações 
gel e comprimido, sobre o debridamento periodontal em fumantes com periodontite 
crônica. Este estudo justifica-se devido serem escassos os trabalhos da literatura que 
avaliaram o efeito do Mtz no tratamento da periodontite crônica em fumantes e não há 
nenhum estudo na literatura que tenha avaliado o uso deste antimicrobiano na formulação 
gel ou em dose oral única de Mtz comprimido, particularmente na concentração de 750mg.  
 No segundo estudo foram determinadas as concentrações plasmáticas e salivares 
obtidas com o gel e comprimido de Mtz, uma vez que o gel de Mtz, por se tratar de uma 
nova formulação, não tem informações sobre suas concentrações plasmáticas e salivares. 
Além disso, informações sobre a farmacocinética destas formulações poderiam ajudar a 
compreender os resultados obtidos com o estudo clínico anterior.  
 A literatura mostrou que o fumo pode promover diminuição na biodisponibilidade 
de alguns medicamentos como irbesartam, fenilbutazona, vecurônio, codeína, morfina, 
teofilina, clozapina e olanzapina (Zhang et al., 2005; Kroon, 2007; Sweeney & Grayling, 
2009). No entanto, não foi encontrado nenhum estudo que tenha avaliado a possível 
influência do fumo na farmacocinética do Mtz, a qual poderia ser relevante, dada a relação 
entre fumo e aumento da gravidade da doença periodontal. Diante disso, o terceiro estudo 
verificou a possível alteração na farmacicinética do Mtz em plasma e saliva quando 
administrado em fumantes. 









 Essa tese está baseada na Informação CCPG/002/06/Unicamp que regulamenta o 
formato alternativo para dissertação e tese e permite a inserção de artigos científicos de 
autoria ou co-autoria do candidato. 
 Desta forma, esta tese é composta de 3 artigos, os quais serão ou foram 
submetidos à publicação, conforme descrito abaixo: 
 
 2.1. – Capítulo 1 - Clinical evaluation of metronidazole gel and tablet on one-
session full-mouth debridement in smokers with chronic periodontitis. 
Será submetido ao Journal of Clinical Periodontology.  
  
 2.2. – Capítulo 2 - Determination of plasmatic and salivary concentrations of 
metronidazole in gel and tablet. 
Será submetido ao Journal of Clinical Pharmacy and Therapeutics. 
 
 2.3. – Capítulo 3 - Effect of smoking on bioavailability of metronidazole tablet in 
plasma and saliva. 
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Objective: The aim of this study was to compare the effect of two metronidazole (Mtz) 
formulations (gel and tablet) on full-mouth periodontal debridement (PD) in smokers with 
chronic periodontitis. Methods: This double-blind, randomized clinical trial involved 30 
patients, having at least five teeth with a probing pocket depth (PPD) of  5 mm. 
Individuals were randomly assigned into three groups: 1) PD combined with 3 g placebo 
gel; 2) PD combined with daily topical application (applied by using a dental tray with gel 
overnight, during 7 days) of 3 g of 15% Mtz benzoate gel; and 3) PD combined with a daily 
single dose of 750 mg Mtz (Flagyl®), during 7 days. Clinical parameters evaluated was 
visible plaque index (VPI), gingival bleeding index (GBI), probing pocket depth (PPD) and 
relative attachment level (RAL) which were assessed preoperatively, after gently 
supragingival calculus scaling (baseline), and after 1, 3 and 6 months after PD. Kruskal-
Wallis test was used to observe intra- and intergroup differences concerning the parameters. 
Results: No statistically significant difference was observed among the groups, considering 
all parameters tested. A significant reduction was observed for GBI at 3 and 6 months when 
compared to baseline (p<0.05); and for PPD and RAL at 1, 3 and 6 months when compared 
to baseline (p<0.05), for all groups. The average PPD reduction at 6 months were 1.8 (1.5-
2.3) mm, 1.8 (1.5-2.4) mm and 2.4 (1.1-2.9) mm; and RAL gain at 6 months were 2.0 (1.7-
2.8) mm, 1.9 (1.0-3.0) mm and 1.8 (1.0-3.8) for groups 1, 2 and 3, respectively. 
Conclusion: Mtz (gel and tablet) did not improve the clinical outcomes provided by PD 
alone in smokers with chronic periodontitis. 















The presence of specific microorganisms is a crucial factor in inflammatory 
periodontal desease; however, it has become apparent that pathogens are necessary, but not 
sufficient, for disease activity to occur. The progression of the disease is related to host-
based risk factors (Kinane & Bartold, 2007). 
Previous studies, investigating the relationship between smoking and periodontal 
destruction, have reported smoking as a risk factor for periodontitis (Calsina et al., 2002; 
Lorentz et al., 2009). Smokers with periodontitis are known to be more susceptible to bone 
attachment loss than nonsmokers (Stoltenberg et al., 1993); moreover, a significant 
reduction in the extent of clinical improvements following periodontal treatment has been 
found in smokers which could have a less favourable response to mechanical therapies 
(Mascarenhas et al. 2005; Heasman et al., 2006; Pahkla et al., 2006, Grossi et al., 2007).  
Several studies have reported that antimicrobial agents associated with the 
periodontal therapy might result in better clinical outcomes in smokers (Loesche et al., 
1992; Kinane & Radvar, 1997; Söder et al., 1999; Winkel et al., 2001, Preshaw et al., 2005; 
Pahkla et al., 2006; Grossi et al., 2007; Matarazzo et al., 2008). Such supplemental 
antimicrobial therapy can be justified by the evidence that smoking and tobacco products 
directly alter the subgingival microbiota, favoring colonization with periodontal pathogens 
(Grossi et al., 1997). In addition, antimicrobial agents have the potential to reduce the 
number of periodontal pathogens in saliva and gingival crevicular fluid (GCF), as well as in 
sites of difficult mechanical instrumentation access. 
Periodontal treatment includes surgical and regenerative techniques, and mechanical 
removal of supra- and subgingival microbial plaques combined or not with locally or 
systemically administered antimicrobial agents (Lopez et al., 2006). The main objective of 
periodontal therapy is to reduce probing pocket depth and bleeding on probing and 
suppuration, as well as to improve the attachment level (Socransky & Haffajee, 2005; Teles 
et al., 2006). 
  Previous studies, comparing full-mouth periodontal debridement (PD) to scaling 
and root planning (SRP) for sextant, showed similar clinical and microbiological results 






patients with chronic periodontitis (Greenstein, 2000; Tomasi et al., 2006; Koshy et al., 
2005; Del Peloso Ribeiro et al., 2008). Furthermore, PD might prevent bacterial re-
infection when compared to SRP, a procedure which could result in a re-infection of the 
treated areas by pathogens residing in non-treated sites or other intraoral niches (Bollen et 
al., 1998). 
  Subgingival microbial plaque is an extremely complex biofilm, protecting the 
bacteria from antimicrobial attack. Antimicrobial agents can only be effective if the oral 
biofilm is initially disrupted by mechanical procedures, thus exposing the periodontal 
pathogens (Mullally et al., 2007).  
  Metronidazole (Mtz) is commonly prescribed for patients with chronic periodontitis 
because of its narrow spectrum, mainly against anaerobic microorganisms responsible for 
the periodontal diseases (Haffajee et al., 2008).  Previous reports suggest that this 
antimicrobial agent, systematically and locally administered, has clinical and 
microbiological benefits, when compared to periodontal therapies using mechanical 
procedures alone, in patients with chronic periodontitis (Griffiths et al., 2000; López et al., 
2000; Pavia et al., 2004; Carvalho et al., 2005; Haffajee et al., 2007; Moeintaghavi et al., 
2007; Haffajee et al., 2008). However, few studies have investigated its antimicrobial effect 
on periodontal pathogens in smokers. Furthermore, there is no study that evaluated its 
antimicrobial effects using a new gel formulation as purposed in the present study.  
The aim of the present study was to evaluate the effect of Mtz in two formulations 
(gel and tablet) on PD in smokers with chronic periodontitis. 
 
Materials and methods 
Study Design 
This parallel, randomized, double-blind study, involving a 6-month follow up, was 
designed to evaluate the effect of a placebo gel (3 g), 15% Mtz benzoate gel (3 g), and 750 
mg Mtz (tablet - Flagyl®) on PD. This study was approved by the Ethical Committee of 
Piracicaba Dental School - University of Campinas, São Paulo, Brazil (#085/2006). All 








A detailed intra-oral examination was used to select 30 individuals from the 
periodontics clinic of Piracicaba Dental School, University of Campinas (UNICAMP), 
considering their medical and dental history. Examinations involved full-mouth periodontal 
probing and radiographic evaluation. 
Inclusion criteria were: 1) diagnosis of chronic periodontitis established by the 
presence of periodontal pockets with a clinical attachment loss of 5 mm, bleeding on 
probing (BOP), and radiographic bone loss (Flemmig, 1999); 2) at least five teeth with a 
probing pocket depth (PPD) of 5 mm and bleeding on probing; 3) at least 20 teeth in their 
mouth (third molars excluded); and 4) smoking habits (at least 10 cigarettes per day for the 
past 4 years). 
Exclusion criteria were: 1) periapical alterations in qualifying teeth; 2) medical 
disorders requiring prophylactic antibiotic therapy or interfering with the treatment; 3) 
periodontal treatment in the past 6 months; 4) use of drugs known to affect periodontal 
status (antibiotic, anti-inflammatory, anticonvulsant, immunosuppressant and calcium 
channel blocker) within the past 6 months; 5) orthodontic therapy; 6) pregnancy and 
lactation; 7) allergy to Mtz; and 8) systemic diseases (e.g.: diabetes and immunological 
disorders) that could intensify the natural progress of the periodontal disease.  
Alcoholic drinks were refrained during the nine-day treatment (Hersh, 1999). 
Subjects were instructed to avoid systemic antimicrobial therapy, chlorhexidine 
mouthrinse, and toothpaste containing antimicrobial agents. Volunteers received the same 
toothpaste, which they were told to use during the study (Colgate Triple Action, Colgate-
Palmolive Ind. Com. Ltda, São Bernardo do Campo, SP, Brazil). 
Drugs 
Mtz benzoate gel (lot#MB/0607/0046A, Amoli Organics, India), 250 mg MTZ 
tablet (Flagyl® - Aventis, lot #700277, São Paulo, Brazil), and a placebo gel were 
purchased in a Farmavip drugstore, São Paulo, Brazil. 
The placebo gel (semi-solid suspension) contained carboxymethylcellulose, nipagin, 
deionized water, sacarine, glycerine and liquid sorbitol. For the Mtz gel, 15% Mtz benzoate 






gingiva, dental trays (Whiteness, Dentscare Ltda, Joinville, Brazil), which are usually used 
for home dental bleaching, were used to apply the gel in the lower and upper jaws. Trays 
were extended 4 mm above the gingival margin. The gel was stored in syringe at 8 °C 
Clinical Protocol 
 Patients received detailed information on the etiology of periodontal disease and 
instructions for self-performed plaque control, including inter-dental flossing and inter-
dental tooth brushing. At the first session, patients had removed the retentive factors 
(caries, excess of restorations, and supragingival calculus) for plaque. Toothpaste (Colgate 
Triple Action, Colgate-Palmolive Ind. Com. Ltda, Sao Bernardo do Campo, SP, Brazil) 
was provided for all volunteers during the study period. Baseline measurements were made 
30 days after these initial procedures.  
 Patients were randomly assigned to one of the following treatments groups (n=10): 
- G 1: Full-mouth debridement + placebo gel; 
- G 2: Full-mouth debridement + Mtz benzoate gel; 
- G 3: Full-mouth debridement + Mtz tablet 
Full-mouth debridement (PD) in all the subjects was performed by the same 
periodontist using an ultrasonic device (Profi III, Dabi Atlante, Ribeirao Preto, Sao Paulo, 
Brazil) in a single session for approximately 1 hour. Subjects were told to use the gel or 
tablets starting at night on the same day of debridement. In addition, they should wear the 
trays with gel (G1 and G2) overnight (approximately 7 hours) or take the single oral dose of 
750 mg tablets (G3) 2 hours after dinner. All the treatments were kept during seven days. 
The Mtz or placebo gels were applied in both upper (1.5 g) and lower (1.5 g) dental arches.  
 One clinician (a calibrated examiner) was responsible for performing the treatment 
and recording clinical parameters, and a second clinician for providing the subjects with the 
drugs. The first operator was blinded to the treatment. 
Re-assessment examination 
All subjects were reassessed by means of an oral maintenance programme 
comprising supragingival plaque control and reinforcement of oral hygiene instructions, 
after 1, 3, and 6 months of the periodontal procedure. At the sixth month, sites having PPD 






to report any possible side effect resulting from the treatments in a self-filled questionnaire 
provided seven days after PD. 
Clinical measurement 
Supragingival biofilm and gingival inflammation, concerning all teeth, were 
evaluated using the visible plaque index (VPI) and the gingival bleeding index (GBI), 
considering four different tooth surfaces: mesial, distal, buccal and lingual (Ainamo & Bay, 
1975). An individual occlusal stent made of self-curing clear resin was used to standardize 
the location and angulation of periodontal probes. The relative attachment level (RAL) was 
measured from the stent to the bottom of periodontal pocket. All these measurements were 
taken by using a periodontal probe (Probe UNC 15 Hu-Friedy, Chicago, IL, USA). The 
clinical parameters were taken at preoperative (first appointment), baseline (30 days after 
supragingival scaling) and 1, 3 and 6 months after PD. 
Drug use compliance 
To measure drug use compliance, saliva (5 mL) was collected from patients (G2 and 
G3) on the eighth day after PD. A previously adapted method (Cássia-Bergamaschi et al., 
2006) was used to analyze Mtz in saliva. The samples were submitted to protein extraction 
using a protein-precipitation solution, resulting in a supernatant with the pH adjusted to 5.4. 
The salivary drug concentration was then detected by means of high performance liquid 
chromatography (HPLC) using a mobile phase (elution solution) consisting of an aqueous 
solution (0.01 M) of sodium monophosphate (pH: 4.7) and acetonitrile (85:15). The 
chromatographic separations were carried out using a Lichrospher column 100 RP18 
(125mm x 4mm x 5µm, Merck, Darnstadt, Germany). The flow rate was 1.0 mL/min and 
the wavelength was set at 320 nm. A standard stock solution of Mtz was diluted in drug-
free saliva (5µg/mL to 0.01µg/mL) to establish the calibration curve and measure the 
salivary drug concentration. . A randomly accessed salivary concentration was detected in 
eight day after PD in all subjects evaluated in concentration from 3.19 to 0.26 µg/mL. 
Subject’s study compliance 
Forty-six patients were evaluated and 30 patients who attended the preoperative 
phase completed the 6-month study. A flow diagram of the study is shown in the Figure 1. 






visits were completed in august 2008. The data entry of all information and statistical 
analysis were performed by the same time. 
Statistical analyses  
 A power calculation was performed before the study and indicated that 10 subjects 
in each group would provide a power higher than 80% to detect a 1 mm difference in 
clinical attachment level between the groups, considering a 5% of significance level.  
 Data were submitted to Levene’s and Shapiro-Wilk’s tests to verify similarity of 
variances and normal distribution, respectively. Analysis of Variance (ANOVA) was used 
to compare the demographic factors among the groups. Neither normal distribution nor 
similar variance was observed; thus, Kruskal-Wallis and Friedmann tests were used to 
observe inter- and intra group differences concerning GBI, VPI, PPD, and RAL. Chi-
Square test was used to verify the proportion of sites presenting RAL gain or PPD 
improved ( 2mm). The analysis was carried out using Software BioEstat 5.0, Mamirauá 
















Figure 1. Flowchart of the study. 
46 patients assessed for
eligibility
Initial phase
16 patients excluded -




10 patients received one session of 
full-mouth periodontal debridement
plus placebo (7 days)
Follow-up at:
1 month: 10 patients
3 months: 10 patients
6 months: 10 patients
10 patients analysed 10 patients analysed 10 patients analysed
10 patients received one session of 
full-mouth periodontal debridement plus
metronidazole benzoate – gel (7 days)
10 patients received one session of 
full-mouth periodontal debridement
plus metronidazole – tablet (7 days)
Follow-up at:
1 month: 10 patients
3 months: 10 patients
6 months: 10 patients
Follow-up at:
1 month: 10 patients
3 months: 10 patients







The demographic data of the patients and full-mouth average values of GBI and VPI 
at baseline for the treatment groups are presented in Table 1. No statistically significant 
differences were observed among groups for any parameter listed in Table 1 (p>0.05).  
 
 Table 1. Mean (±SD) of demographic patient date and clinical parameters at 
baseline. 
Variables 
PD + Placebo Gel 
(n=10) 
PD + Mtz Gel 
(n=10) 
PD + Mtz Tablet 
(n=10) 
Gender (male/female) 4/6 4/6 4/6 
Age (years) 45.0 ± 5.70 42.7 ± 5.98 45.7 ± 8.30 
Number of smoking/day 16.7 ± 4.47 13.8 ± 5.14 18.1 ± 5.66 
% sites PPD  4 mm 74.7 ± 12.34 77.1 ±16.69 71.6 ± 21.25 
% sites PPD 5 to 6 mm 18.56 ± 7.51 24.71 ± 21.42 17.08 ± 9.29 
% sites PPD  7 mm 7.3 ± 5.94 5.8 ± 5.07 9.6 ± 9.51 
%VPI at baseline 51.7 ± 24.64 45.8 ± 24.45 44.8 ± 20.13 
% GBI at baseline 36.9 ± 19.04 30.3 ± 14.92 34.9 ± 18.37 
No significant difference (ANOVA) was observed considering age, number of smoking/day, % PPD. 
No significant difference (Kruskal-Wallis) was observed considering GBI and VPI. 
Values of VPI and GBI refer to means of the whole mouth. 
Periodontal procedure (PD), metronidazole (Mtz), visible plaque index (VPI), gingival bleeding index (GBI) 
and probing pocket depth (PPD)  
 
Clinical results 
VPI and GBI 
Changes in GBI and VPI among periods of time and groups are presented in Figure 
2. No statistically significant differences among the groups were observed for both GBI and 
VPI (p>0.05). A significant reduction was observed for all groups in mean GBI at 3 and 6 






25.5% (PD plus tablet), from 30.3% to 22.4% (PD plus Mtz gel) and from 34.9% to 27.9% 
(PD). 
No significant reduction was observed for all groups in mean VPI at 3 and 6 months 
to baseline (p>0.05), however this standard of oral hygiene was maintained, or even 
















Figure 2. Lines represent visible plaque index – VPI values (mean ± SEM) and bars 
represent gingival bleeding index – GBI values (mean ± SEM) at the three time intervals 
for each treatment groups.  
 
Probing Assessments: PPd and RAL of the qualified sites 
Figure 3 shows the probing assessments (median – interquartile range) PPD and 
RAL. PPD and RAL were improved (p<0.05) in all the groups, starting from the first 
month until the last period evaluated. However, no statistically significant differences 






































































































Figure 3. Median values (interquartile range) of PPD and RAL of all groups 
according to the time periods. Different letters mean statistically significant differences 
(p<0.05) among time intervals and groups.  
 
Table 2 summarizes RAL gain and PPD reduction considering all groups after 1, 3 
and 6 months from baseline measurement. Both PPD reduction and RAL gain (p>0.05) did 
not differ among groups or among periods of time. Changes in RAL for each subject at 6 
months from the baseline showed that there are no differences among groups. These results 
















































































































































































































































































































































































































































































































































































PD + MTZ tablet
PD + MTZ gel    
 Table 2. PPD reduction and RAL gain values of all groups after 1, 3 and 6 months 
from baseline measurement. 
PPD reduction (in mm) RAL gain (in mm) 
  Median (1st – 3rd quartiles) Median (1st – 3rd quartiles) 
Groups 1 month 3 months 6 months 1 month 3 months 6 months 
2 1.8 1.8 1.8 2 2 
PD (1.7 – 2.0) (1.4 – 2.0) (1.5 – 2.3) (1.3 – 3.6) (1.2 – 2.8) (1.7 – 2.8) 
1.6 1.8 2.4 1.8 1.6 1.8 
PD + Mtz Tablet (1.5 – 2.8) (1.1 – 3.3) (1.1 – 2.9) (1.4 – 3.3) (1.0 – 3.8) (1.0 – 3.8) 
1.6 1.9 1.8 1.6 1.8 1.9 
PD + Mtz Gel (1.1 – 1.8) (1.7 – 2.6) (1.5 – 2.4) (1.0 – 3.0) (1.0 – 2.8) (1.0 – 3.0) 
No significant differences were observed intergroup (p>0.05) and intragroup (p>0.05) to PPD reduction and 
RAL gain. (periodontal debridement - PD, metronidazole - Mtz, probing pocket depth - PPD and relative 




















The probing assessments were further analyzed with respect to proportions of sites 
showing 2mm change PPD and RAL (Table 3). There was no difference between the 
treatments approaches regarding the proportions of sites presenting a RAL gain or PPD 
improved ( 2mm) at any experimental time (p>0.05).  
 
Treatment Discomfort  
All subjects completed the study in good health conditions. No effect adverse was 
related due to the periodontal procedure. Gastrointestinal intolerance was observed in one 
subject right after using Mtz tablet (10%). An increase in salivation was observed in eight 
subjects using gels (40%), and five subjects reported bitter flavor during the use of the Mtz 
gel (50%). These effects did not interfere in or cause interruption of the treatment, and all 
subjects reported full adherence to the treatments. 
 
Table 3. Number (percentage) of sites that showing RAL gain (2 mm) and PPD 
reduction (2 mm) to groups according to the time intervals. 
 PPD Improved ( 2 mm) RAL Gain ( 2 mm) 












































p values 0.2407 0.0669 0.9698 0.607 0.6585 0.5455 
No significant differences were observed (Chi-Square test, p>0.05) towards PPD improvement (2 mm) and 
RAL gain (2 mm). (periodontal debridement - PD, metronidazole - Mtz, probing pocket depth – PPD and 








Smokers have been reported to respond to the mechanical periodontal treatment less 
favorably than non-smokers (Winkel et al. 2001, Darby et al. 2005, Mascarenhas et al. 
2005, Heasman et al. 2006, Hughes et al. 2006, Pahkla et al. 2006, Grossi et al. 2007). 
Also, a higher recurrence of periodontal disease has been associated with cigarette smoke 
(MacFarlane et al., 1992; Loesche et al., 2002; Quirynen et al., 2006).  
In the present study, the choice of Mtz, systemically and topically administered, was 
based on clinical and microbiological benefits reported in previous studies aimed at the 
treatment for chronic periodontitis in smokers (Loesche et al., 1992; Soder et al., 1999, 
Griffiths et al., 2000; Winkel et al., 2001; Pahkla et al., 2006; Matarazzo et al., 2008;) and 
non-smokers (Elter et al., 1997; Lopez et al., 2000; Pavia et al., 2004; Carvalho et al., 2005, 
Ehmke et al., 2005; Loesche et al., 2005; Moeintaghavi et al., 2007; Haffajee et al., 2007; 
2008).  
The literature shows different local antimicrobial delivery systems for treating 
periodontal pockets using some gel formulations as follows: 5% Mtz with collagen gel 
(Hitzig et al., 1994); 25% Mtz benzoate with monoglyceride triglyceride gel (Stoltze and 
Stellfeld, 1992); 15% Mtz benzoate with chitosan gel (Akıncıbay et al., 2006); among 
others. To our knowledge, the present study is the first to evaluate the effect of 15% Mtz 
benzoate gel applied by using a custom dental tray system. This tray system was chosen to 
keep Mtz very close to the gingival and periodontal tissues. In addition, it could maintain a 
relative concentration for an extended period of time. 
Despite the flow rate of the gingival crevice fluid (GCF), which was estimated by 
Goodson (1989) to be replaced 40 times during one hour in a pocket, the dental tray system 
could allow a high antimicrobial concentration at the diseased sites. Drugs applied directly 
into periodontal pockets are easily eliminated due to the crevicular fluid flow, but the 
contact of gel used in the present study could be maintained during overnight allowing a 
continuous replacement of the antimicrobial agent into the pocket. Furthermore, a less 
systemic absorption of Mtz could be achieved. However, the Mtz benzoate, chosen in the 
present study as the main active compound of the gel, could not have the ideal properties to 






Mtz benzoate, a benzoic acid ester of Mtz, is generally preferred in oral 
formulations due to its less bitter taste when compared to Mtz (Baeyens et al., 1998). In the 
present study, the Mtz benzoate and placebo gel formulations were considered safe for 
periodontal therapies since no side effect was reported by subjects. 
Several studies have investigated systemically Mtz in different oral dosages: 250 
mg (t.i.d.) (Loesche et al., 1991); 400 mg (t.i.d.) (Soder et al., 1999; López et al., 2000; 
Feres et al., 2001; Guerrero et al., 2005; López et al., 2006; Xajigeorgiou et al., 2006); and 
500 mg (t.i.d.) (Carvalho et al., 2004; 2005; D’avila et al., 2005).  However, this is the first 
study evaluating the effect of a single oral dose of 750 mg Mtz in the periodontal treatment.  
The results of the current study revealed that antimicrobial therapy had similar 
clinical improvement with that achieved by the full mouth periodontal debridement (PD) 
alone, considering all parameters evaluated. The magnitude of the clinical improvement to 
the treatments was similar to the previously published data. Wilkell et al. (2001) reported a 
PPD reduction of 1.4 mm after 3-months treatment and relative attachment gain 2 mm of 
25.1% in smokers treated with systemic Mtz (250 mg) plus amoxicillin (375 mg) 
(t.i.d/8days) after PD. Matarazzo et al. (2008) observed that use of 400 mg (t.i.d.) Mtz 
tablets for 14 days combined with scaling and root planning (SRP) improved PPD (1.3 mm) 
and RAL (1.4 mm) after 3-months of periodontal treatment, showing similar values with 
the ones obtained in the present study.  
The traditional approach of quadrant-wise SRP is considered as an effective 
treatment for periodontal disease (Leiknes et al., 2007). However, a concern regarding 
microbial recolonization and the level of instrumentation required for periodontal healing 
exists (Kinane, 2005). During the PD procedure, all teeth are instrumented during a single 
session for a restricted period of time. Several studies verified that PD resulted in a similar 
clinical and microbiological outcome compared to SRP (Wennstrom et al., 2005; Koshy et 
al., 2005; Zanatta et al., 2006; Tomasi et al., 2006; Del Peloso et al., 2008).  
Tomasi et al. (2006) and Wennstrom et al. (2005) reported clinical results similar to 
observed in the present study. Tomasi et al. (2006) reported a similar PPD improved at 6-






and RAL gain of 1.2-1.3mm at 3-months after PD in smokers. Similar results too were 
obtained to PPD improved (2mm) and RAL gain (2mm).  
As observed in the present study, Palmer et al. (1999) also found no additional 
benefits in the systemic use of Mtz associated wit SRP (200 mg, t.i.d., for 7 days) or in the 
subgingival application of 25% Elyzol® (Mtz gel) in smokers with moderate or severe 
chronic periodontitis. Van Winkelhoff et al. (1999) related that the low antimicrobial dose, 
as used in tablet formulations, could be responsible for the lack of clinical efficacy. In the 
present study, the dose used (750mg in tablets - or 3g in the 15% benzoate gel) or the 
duration of the treatments (7 days), could not reached the ideal concentration and time for 
the bacterial elimination and consequently to obtain additional clinical improvement. PD 
could be also quite effective in producing clinically improvements, since it was performed 
by an experienced periodontist, masking the antimicrobial effect. 
Previous studies reported that the periodontal treatment associated with Mtz was more 
effective in deep pockets than shallow pockets (Jenkins et al., 1989; Loesche et al. 1992; 
2002; Eisenberg et al., 1991; Noyan et al., 1997; Feres et al., 2001; Carvalho et al., 2004). 
The volunteers of the present study showed a few percentages of sites with deep pockets  
7mm (5.8 to 9.6%), which could also masked any additional clinical benefit of the 
antimicrobial therapy.  
Smokers that received Mtz associated with periodontal procedure showed no 
additional clinical benefit of this antimicrobial agent (Leiknes et al., 2007; Jansson et al., 
2003; Lie et al., 1998; Palmer et al., 1999). Jansson et al. (2003) observed no difference 
comparing 25% Mtz gel combined with SRP and SRP alone. Like others, MacFarlane et 
al., 1992 and Loesche et al., 2002 related highest incidence of the disease recurrence in 
smokers. The lower reduction of subgingival microbial load following pocket 
instrumentation (Van Winkelhoff et al., 2001; Van der Velden et al., 2003) and the 
impaired host response (Labriola et al., 2005; Palmer et al., 2005) are pointed as possible 
explanation to the reduced effectiveness of periodontal treatment in smokers.  
This paper updates the previous 6-months report on the efficacy of topical and 
systemic Mtz for the treatment of chronic periodontitis. The data showed to be favorable 






and gel showed the same clinical outcome. 
 
Conclusion 
The association of metronidazole (gel or tablet) with periodontal debridment 
resulted in no improvement in the clinical outcome in smokers with chronic periodontitis, 
compared to periodontal debridment alone. 
 
Acknowledgements 
 The authors thank FAPESP (Brazilian Funding Institution – grant protocol 




Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J. 
1975 Dec;25(4):229-35. 
Akncbay H, Senel S, Ay ZY. Application of chitosan gel in the treatment of chronic 
periodontitis. J Biomed Mater Res B Appl Biomater. 2007 Feb;80(2):290-6. 
Baeyens WR, Van der Weken G, Van Overbeke A, De Meyer S, García Campaña AM, 
Kiekens P, Remon JP, Dewaele C. Narrow-bore reversed-phase liquid chromatography of 
metronidazole benzoate and its hydrolysis products. Biomed Chromatogr. 1998 May-
Jun;12(3):164-6.                                                                                                              
Bollen CM, Mongardini C, Papaioannou W, Van Steenberghe D, Quirynen M. The effect 
of an one-stage full-mouth disinfection on different intra-oral niches. Clinical and 
microbiological observations. J Clin Periodontol. 1998 Jan;25(1):56-66. 
Calsina G, Ramón JM, Echeverría JJ. Effects of smoking on periodontal tissues. J Clin 
Periodontol. 2002 Aug;29(8):771-6. 
Carvalho LH, D'Avila GB, Leão A, Gonçalves C, Haffajee AD, Socransky SS, Feres M. 






treatment of chronic periodontitis in a Brazilian population II: microbiological results. J 
Periodontol. 2005 Apr;32(4):406-11. 
Carvalho LH, D'Avila GB, Leão A, Haffajee AD, Socransky SS, Feres M. Scaling and root 
planing, systemic metronidazole and professional plaque removal in the treatment of 
chronic periodontitis in a Brazilian population. I. clinical results. J Clin Periodontol. 2004 
Dec;31(12):1070-6. 
Darby IB, Mooney J, Kinane DF. Changes in subgingival microflora and humoral immune 
response following periodontal therapy. J Clin Periodontol. 2001 Aug;28(8):796-805.  
D'Avila GB, Carvalho LH, Feres-Filho EJ, Feres M, Leão A. Oral health impacts on daily 
living related to four different treatment protocols for chronic periodontitis. J Periodontol. 
2005 Oct;76(10):1751-7. 
Del Peloso Ribeiro E, Bittencourt S, Sallum EA, Nociti FH Jr, Gonçalves RB, Casati MZ. 
Periodontal debridement as a therapeutic approach for severe chronic periodontitis: a 
clinical, microbiological and immunological study. J Clin Periodontol. 2008 Sep;35(9):789-
98.Epub 2008 Jul 21.                                                                                                       
Ehmke B, Moter A, Beikler T, Milian E, Flemmig TF. Adjunctive antimicrobial therapy of 
periodontitis: long-term effects on disease progression and oral colonization. J Periodontol. 
2005 May;76(5):749-59. 
Eisenberg L, Suchow R, Coles RS, Deasy MJ. The effects of metronidazole administration 
on clinical and microbiologic parameters of periodontal disease. Clin Prev Dent. 1991 
Jan;13(1):28-34. 
Elter JR, Lawrence HP, Offenbacher S, Beck JD. Meta-analysis of the effect of systemic 
metronidazole as an adjunct to scaling and root planing for adult periodontitis. J Periodontal 
Res. 1997 Aug;32(6):487-96. 
Feres M, Haffajee AD, Allard K, Som S, Socransky SS. Change in subgingival microbial 
profiles in adult periodontitis subjects receiving either systemically-administered 
amoxicillin or metronidazole. J Clin Periodontol. 2001 Jul;28(7):597-609.  
Flemmig TF. Periodontitis. Ann Periodontol. 1999 Dec;4(1):32-8. Review. 
Goodson J. Pharmacokinetic principles controlling efficacy of oral therapy. J Dent Res. 






Greenstein G. Nonsurgical periodontal therapy in 2000: a literature review. J Am Dent 
Assoc. 2000 Nov;131(11):1580-92.  
Griffiths GS, Smart GJ, Bulman JS, Weiss G, Shrowder J, Newman HN. Comparison of 
clinical outcomes following treatment of chronic adult periodontitis with subgingival 
scaling or subgingival scaling plus metronidazole gel. J Clin Periodontol. 2000 
Dec;27(12):910-7.                                                                                                            
Grossi SG, Goodson JM, Gunsolley JC, Otomo-Corgel J, Bland PS, Doherty F, Comiskey 
J. Mechanical therapy with adjunctive minocycline microspheres reduces red-complex 
bacteria in smokers. J Periodontol. 2007 Sep;78(9):1741-50. 
Grossi SG, Zambon J, Machtei EE, Schifferle R, Andreana S, Genco RJ, Cummins D, 
Harrap G. Effects of smoking and smoking cessation on healing after mechanical 
periodontal therapy. J Am Dent Assoc. 1997 May;128(5):599-607 
Guerrero A, Griffiths GS, Nibali L, Suvan J, Moles DR, Laurell L, Tonetti MS. Adjunctive 
benefits of systemic amoxicillin and metronidazole in non-surgical treatment of generalized 
aggressive periodontitis: a randomized placebo-controlled clinical trial. J Clin Periodontol. 
2005 Oct;32(10):1096-107. 
Haffajee AD, Patel M, Socransky SS. Microbiological changes associated with four 
different periodontal therapies for the treatment of chronic periodontitis. Oral Microbiol 
Immunol. 2008 Apr;23(2):148-57. 
Haffajee AD, Torresyap G, Socransky SS. Clinical changes following four different 
periodontal therapies for the treatment of chronic periodontitis: 1-year results. J Clin 
Periodontol.2007Mar;34(3):243-53.                                                                                 
Heasman L, Stacey F, Preshaw PM, McCracken GI, Hepburn S, Heasman PA. The effect of 
smoking on periodontal treatment response: a review of clinical evidence.J Clin 
Periodontol. 2006 Apr;33(4):241-53. Review. 
Hersh EV. Adverse drug interactions in dental practice: interactions involving antibiotics. 
Part II of a series. J Am Dent Assoc. 1999 Feb;130(2):236-51. 
Hughes FJ, Syed M, Koshy B, Bostanci N, McKay IJ, Curtis MA, Marcenes W, Croucher 






of smoking on initial outcome. J Clin Periodontol. 2006 Sep;33(9):671-6. Epub 2006 Jul 
20. 
Jansson H, Bratthall G, Söderholm G. Clinical outcome observed in subjects with recurrent 
periodontal disease following local treatment with 25% metronidazole gel. J Periodontol. 
2003 Mar;74(3):372-7. 
Jenkins WM, MacFarlane TW, Gilmour WH, Ramsay I, MacKenzie D. Systemic 
metronidazole in the treatment of periodontitis. J Clin Periodontol. 1989 Aug;16(7):443-50. 
Kinane DF, Radvar M. The effect of smoking on mechanical and antimicrobial periodontal 
therapy. J Periodontol. 1997 May;68(5):467-72. 
Kinane DF. Single-visit, full-mouth ultrasonic debridement: a paradigm shift in periodontal 
therapy? J Clin Periodontol. 2005 Jul;32(7):732-3.        
Kinane DF, Mark Bartold P. Clinical relevance of the host responses of periodontitis. 
Periodontol 2000. 2007;43:278-93. Review.                                           
Koshy G, Kawashima Y, Kiji M, Nitta H, Umeda M, Nagasawa T, Ishikawa I. Effects of 
single-visit full-mouth ultrasonic debridement versus quadrant-wise ultrasonic debridement. 
J Clin Periodontol. 2005 Jul;32(7):734-43. 
Labriola A, Needleman I, Moles DR. Systematic review of the effect of smoking on 
nonsurgical periodontal therapy. Periodontol 2000. 2005;37:124-37.  
Leiknes T, Leknes KN, Böe OE, Skavland RJ, Lie T. Topical use of a metronidazole gel in 
the treatment of sites with symptoms of recurring chronic inflammation. J Periodontol. 
2007 Aug;78(8):1538-44. 
Lie T, Bruun G, Böe OE. Effects of topical metronidazole and tetracycline in treatment of 
adult periodontitis. J Periodontol. 1998 Jul;69(7):819-27. 
Loesche WJ, Giordano JR. Hujoel P, Schwarcz J, Smith BA. Metronidazole in 
periodontitis: reduced need for surgery.  J Clin Periodontol. 1992 Feb;19(2):103-12. 
Loesche WJ, Giordano JR, Soehren S, Kaciroti N. The nonsurgical treatment of patients 
with periodontal disease: results of five years. J Am Dent Assoc. 2002 Mar;133(3):311-20. 
Loesche WJ, Giordano JR, Soehren S, Kaciroti N. The nonsurgical treatment of patients 







López NJ, Gamonal JA, Martinez B. Repeated metronidazole and amoxicillin treatment of 
periodontitis. A follow-up study. J Periodontol. 2000 Jan;71(1):79-89.                          
López NJ, Socransky SS, Da Silva I, Japlit MR, Haffajee AD. Effects of metronidazole 
plus amoxicillin as the only therapy on the microbiological and clinical parameters of 
untreated chronic periodontitis. J Clin Periodontol. 2006 Sep;33(9):648-60. 
Lorentz TC, Cota LO, Cortelli JR, Vargas AM, Costa FO. Prospective study of complier 
individuals under periodontal maintenance therapy: analysis of clinical periodontal 
parameters, risk predictors and the progression of periodontitis. J Clin Periodontol. 2009 
Jan;36(1):58-67.  
MacFarlane GD, Herzberg MC, Wolff LF, Hardie NA. Refractory periodontitis associated 
with abnormal polymorphonuclear leukocyte phagocytosis and cigarette smoking. J 
Periodontol. 1992 Nov;63(11):908-13. 
Mascarenhas P, Gapski R, Al-Shammari K, Hill R, Soehren S, Fenno JC, Giannobile WV, 
Wang HL Clinical response of azithromycin as an adjunct to non-surgical periodontal 
therapy in smokers. J Periodontol. 2005 Mar;76(3):426-36. 
Matarazzo F, Figueiredo LC, Cruz SE, Faveri M, Feres M. Clinical and microbiological 
benefits of systemic metronidazole and amoxicillin in the treatment of smokers with 
chronic periodontitis: a randomized placebo-controlled study. J Clin Periodontol. 2008 
Oct;35(10):885-96.                                                                                                               
Moeintaghavi A, Talebi-ardakani MR, Haerian-ardakani A, Zandi H, Taghipour S, 
Fallahzadeh H, Pakzad A, Fahami N. Adjunctive effects of systemic amoxicillin and 
metronidazole with scaling and root planing: a randomized, placebo controlled clinical trial. 
J Contemp Dent Pract. 2007 Jul 1;8(5):51-9.  
Mullally B, Irwin C, Ziada H, Allen E, Byrne PJ. Periodontics: 3. Non-surgical periodontal 
therapy in general dental practice. Dent Update. 2007 Jul-Aug;34(6):326-8, 330-2, 335-6. 
Nagy K, Urban E, Fazekas O, Thurzo L, Nagy E. Controlled study of lactoperoxidase gel 







Noyan U, Yilmaz S, Kuru B, Kadir T, Acar O, Büget E. A clinical and microbiological 
evaluation of systemic and local metronidazole delivery in adult periodontitis patients. J 
Clin Periodontol. 1997 Mar;24(3):158-65.  
Pahkla ER, Koppel T, Naaber P, Saag M, Loivukene K. The efficacy of non-surgical and 
systemic antibiotic treatment on smoking and non-smoking periodontitis patients. 
Stomatologija. 2006;8(4):116-21 
Palmer RM, Wilson RF, Hasan AS, Scott DA. Mechanisms of action of environmental 
factors--tobacco smoking. J Clin Periodontol. 2005;32 Suppl 6:180-95.  
Palmer RM, Matthews JP, Wilson RF. Non-surgical periodontal treatment with and without 
adjunctive metronidazole in smokers and non-smokers. J Clin Periodontol. 1999 
Mar;26(3):158-63Pavia M, Nobile CG, Bianco A, Angelillo IF Meta-analysis of local 
metronidazole in the treatment of chronic periodontitis. J Periodontol. 2004 Jun;75(6):830-
8.  
Preshaw PM, Hefti AF, Bradshaw MH.Adjunctive subantimicrobial dose doxycycline in 
smokers and non-smokers with chronic periodontitis. J Clin Periodontol. 2005 
Jun;32(6):610-6. 
Quirynen M, De Soete M, Boschmans G, Pauwels M, Coucke W, Teughels W, van 
Steenberghe D. Benefit of "one-stage full-mouth disinfection" is explained by disinfection 
and root planing within 24 hours: a randomized controlled trial. J Clin Periodontol. 2006 
Sep;33(9):639-47. Epub 2006 Jul 20. 
Söder B, Nedlich U, Jin LJ. Longitudinal effect of non-surgical treatment and systemic 
metronidazole for 1 week in smokers and non-smokers with refractory periodontitis: a 5-
year study. J Periodontol. 1999 Jul;70(7):761-71. 
Stoltenberg JL, Osborn JB, Pihlstrom BL, Herzberg MC, Aeppli DM, Wolff LF, Fischer 
GE. Association between cigarette smoking, bacterial pathogens, and periodontal status. J 
Periodontol. 1993 Dec;64(12):1225-30. 
Stoltze K, Stellfeld M. Systemic absorption of metronidazole after application of a 
metronidazole 25% dental gel. J Clin Periodontol. 1992 Oct;19(9 Pt 2):693-7. 
Teles RP, Haffajee AD, Socransky SS. Microbiological goals of periodontal therapy. 1: 






Tomasi C, Bertelle A, Dellasega E, Wennström JL. Full-mouth ultrasonic debridement and 
risk of disease recurrence: a 1-year follow-up. J Clin Periodontol. 2006 Sep;33(9):626-31. 
Epub 2006 Jul 20. 
Van der Velden U, Varoufaki A, Hutter JW, Xu L, Timmerman MF, Van Winkelhoff AJ, 
Loos BG. Effect of smoking and periodontal treatment on the subgingival microflora. J 
Clin Periodontol. 2003 Jul;30(7):603-10.  
Van Winkelhoff AJ, Winkel EG, Vandenbroucke-Grauls CM. On the dosage of antibiotics 
in clinical trials. J Clin Periodontol. 1999 Nov;26(11):764-6. 
Van Winkelhoff AJ, Bosch-Tijhof CJ, Winkel EG, van der Reijden WA. Smoking affects 
the subgingival microflora in periodontitis. J Periodontol. 2001 May;72(5):666-71. 
Wennström JL, Tomasi C, Bertelle A, Dellasega E. Full-mouth ultrasonic debridement 
versus quadrant scaling and root planing as an initial approach in the treatment of chronic 
periodontitis. J Clin Periodontol. 2005 Aug;32(8):851-9.  
Winkel EG, Van Winkelhoff AJ, Timmerman MF, Van der Velden U, Van der Weijden 
GA. Amoxicillin plus metronidazole in the treatment of adult periodontitis patients. A 
double-blind placebo-controlled study. J Clin Periodontol. 2001 Apr;28(4):296-305. 
Xajigeorgiou C, Sakellari D, Slini T, Baka A, Konstantinidis A. Clinical and 
microbiological effects of different antimicrobials on generalized aggressive periodontitis. J 
ClinPeriodontol. 2006 Apr;33(4):254-64.   
Zanatta GM, Bittencourt S, Nociti FH Jr, Sallum EA, Sallum AW, Casati MZ. Periodontal 
debridement with povidone-iodine in periodontal treatment: short-term clinical and 











Determination of plasmatic and salivary concentrations of metronidazole in gel and tablet. 
 
Cristiane de Cássia Bergamaschi, PharmD, MSca 
Karina Cogo, PharmD, PhDa 
Paulo Venâncio MSc studenta 




aPiracicaba Dental School – State University of Campinas – Department of Pharmacology, 







Francisco Carlos Groppo  
Faculdade de Odontologia de Piracicaba – UNICAMP  
Av. Limeira, 901, 13414-903  
Piracicaba, SP, Brazil.  
Phone/Fax: +55 19 3412 5310 












Objectives: To compare Mtz gel and tablet concentrations in both blood plasma and 
saliva. In addition, the pharmacokinetic profile of Mtz tablet was determined. Methods: In 
this randomized crossover study with a one-week washout period, 13 volunteers randomly 
received 1) a single oral dose of 750 mg Mtz (FLagyl® - tablet) and 2) 3 g of 15% Mtz 
benzoate gel (applied by using a dental tray, overnight). Blood and saliva samples were 
collected at baseline and 30 min, 1, 1.5, 2, 4, 6, 8, 12, 24 and 48 hours after Mtz tablet 
administration and at 8, 9, 12, 13, 15, 19, 32, and 56 hours after gel application. High-
performance liquid chromatography (HPLC) with UV detection was used to quantify 
plasmatic and salivary concentrations of Mtz. Pharmacokinetic parameters (AUC, Cmax, 
Tmax, VD and CL) of Mtz tablet were determined. Paired Student's t test was used to 
compare the pharmacokinetic parameters and the plasmatic and salivary concentrations of 
Mtz. Results: The values obtained for AUC0-48, Cmax and Tmax regarding Mtz tablet were: 
197.8 µg.h/ml (± 47.88); 11.3 µg/ml (± 2.06); 1.96 h (± 0.72) for plasma; and 115.1 
µg.h/ml (± 59.36); 11.8 µg/ml (± 7.9); 1.35 h (± 0.55) for saliva. Plasma showed higher 
Mtz concentration from 6 to 24 hours after drug administration and the highest values 
concerning Tmax, AUC0-48h and AUC0-∞ than those obtained in saliva (p<0.05). No 
significant differences were observed between salivary and plasmatic concentrations for 
Mtz gel considering all periods tested (p>0.05). Conclusions: Gel formulation had similar 
Mtz bioavailability in plasma and saliva and the bioavailability of Mtz tablet was higher in 
plasma than in saliva. 















 Metronidazole (Mtz), belongs to the nitroimidazole family, it is active against a 
wide variety of anaerobic protozoa parasites and anaerobic bacteria (Dilger et al., 2007). It 
is one of the most widely used antimicrobials in the treatment for periodontal diseases that 
do not react favorably to the conventional treatment (Pahkla et al., 2005). 
Usually, drug dosage schemes are based on empirical data rather than on drug 
pharmacokinetics for specific purposes (Slots & Ting, 2002). Systemic use of Mtz for 
periodontal treatment has been evaluated in different oral doses: 250 mg - 3 times/day 
(Loesche, 1991); 400 mg - 3 times/day (López & Gamonal, 1998, Soder et al., 1999; Feres 
et al., 2001; Guerrero et al., 2005; López et al., 2006; Xajigeorgiou et al., 2006); and 500 
mg - 3 times/day (Carvalho et al., 2004; 2005; D’avila et al., 2005). 
Mtz results in excellent oral absorption (Spénard et al., 2004) and oral 
bioavailability (>90%) is generally reported (Lau et al., 1992; Lamp et al., 1999), with 
tissue concentrations generally similar to or slightly lower than those measured in the 
serum (Sprandel et al., 2004). The blood serum protein binding is 10 to 15% (Lamp et al., 
1999). This drug undergoes hepatic metabolism resulting in two main oxidative products: 
hydroxy and acetic acid metabolites (Jessa et al., 1996). Mtz and its metabolites are mostly 
excreted via renal excretion and up to 77% of the dose is recovered in the urine as 
unchanged drug (10%) or metabolites (90%) (Sprandel et al., 2004). 
The plasmatic and salivary Mtz concentrations were determined by using High-
performance liquid chromatography (HPLC) according to techniques previously described 
(Van Oosten et al., 1986; Jessa et al., 1996; Spénard et al., 2004; Pahkla et al., 2005; Dilger 
et al., 2007). Knowledge of pharmacokinetic properties of drugs might be useful in 
understanding how pharmacokinetic parameters can affect the drug regimen and its clinical 
use (Patsalos, 2004).  
The benzoate, chemically a benzoyl ester, is Mtz prodrug (Lahiani-Skiba et al., 
2006). Benzoate is generally preferred in oral formulations due to the bitter taste of the Mtz 
(Baeyens et al., 1998). The use of Mtz benzoate gel, in different formulations, was 
described in previous studies investigating periodontal diseases (Stoltze and Stellfeld, 1992; 






effect applied inside the periodontal pocket. In the present study was described the 
plasmatic and salivary concentrations of the new formulation of Mtz benzoate gel (15%) to 
the treatment of chronic periodontitis, that was applied by using a custom dental tray 
system. 
The aim of present study was to compare a new Mtz gel formulation with Mtz 
tablet, in both plasmatic and salivary concentrations. In addition, the pharmacokinetic 
profile of Mtz tablet was determined. 
  
Materials and methods 
Study Design 
This study was conducted in an open, randomized, two-period, crossover balanced 
design with a one-week washout period between doses. This study was approved by the 
Ethical Committee of Piracicaba Dental School - University of Campinas, São Paulo, 
Brazil (#086/2006). All participants gave written informed consent and were informed of 
the nature of the study in detail. 
 
Subject Population 
This study consisted of thirteen healthy male volunteers, aged 18 to 30 years-old (22 
± 1.5 years), weighing 65 to 90 kg (74.5 ± 7.9 kg), and 1.69 to 1.90 m (1.8 ± 0.1 m) in 
height. The index of body mass was 21.3 to 27.8 kg/m2 (23.6 ± 2.3 kg/m2). Volunteers were 
free from cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, hematological 
diseases, psychiatric disorders, diabetes, glaucoma and allergy to antimicrobials. 
Subjects were instructed to avoid any kind of drug therapy for at least 4 weeks prior 
to study and up to its completion. They were also refrained from cigarette, and xanthine-
containing foods as well as beverages such as tea, coffee, and cola, 48 hours prior to each 
dosing and until the last blood and saliva sample was collected (Kim et al., 2001).  They 
were also refrained from alcoholic drinks up to a period of 48 hours before and after the last 
sampling due to risk of drug interaction, as Mtz has the ability to produce disulfiram-like 








Mtz benzoate gel (lot#MB/0607/0046A, Amoli Organics, India) and Mtz tablet (250 
mg, Flagyl® - Aventis, lot #700277, São Paulo, Brazil) were obtained in a Farmavip 
drugstore, São Paulo, Brazil. 
The gel comprised a semi-solid suspension containing 15% Mtz benzoate, 
carboxymethylcellulose, nipagin, deionized water, sacarine, glycerine and liquid sorbitol. 
Dental trays (Whiteness, Dentscare Ltda, Joinville, Brazil), which are usually used for 
home dental bleaching, were used to apply the gel in the lower and upper jaws. Trays were 
extended 4 mm above the gingival margin. The gel was stored in syringe at 8 °C. 
 
Chemicals 
 Mtz and the tinidazole (internal standard) were provided by Sigma (St Louis, MO, 
USA). All reagents were of analytical grade. Acetonitrile were obtained from J.T. Baker 
Co. (Phillipsburg, NJ, USA). Sodium hydroxide 1N and perchloric acid (70%, w/v) were 
obtained from Merck (Darmstat, Germany). Distilled water was purified in a Millipore 
system Milli Q. 
 
Clinical Protocol  
Blood and saliva collections were carried out at the ambulatory of Piracicaba Dental 
School (UNICAMP, SP, Brazil). The volunteers were observed and instructed to inform of 
any adverse event during the study. 
After a 12-hour fasting period, the subjects received a single oral dose of 750 mg 
Mtz with water (200 mL). Two hours after drug administration, they had a standard 
breakfast (a cup of peach juice and a 50-g bread loaf with margarine) and were allowed to 
consume water ad libitium. A complete standardized meal (lunch) was allowed four hours 
after drug administration. Blood samples (5 mL)  from antecubital vein via heparinized 
cannula and saliva samples (3 mL) were collected at pre-dose (0), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 
24 and 48 hours after oral administration of Mtz tablets.  
Subjects were told to apply 3 g (1.5 g each jaw) of 15% Mtz benzoate gel (Mtz gel) 






stimulated - 3 mL) samples were collected at 8, 9, 12, 13, 15, 19, 32, and 56 hours after gel 
application. The first collection (8 h) was performed at eight o’clock in the morning.  
The blood sample was collected by direct venepuncture into sterile tubes containing 
K3EDTA solution. The heparinized saline solution (0.9% NaCl and heparine, 9.8:0.2) 
injection (0.2 mL) was flushed into the cannula to prevent blood clotting, after each blood 
sampling. The 24 and 48 hours (Mtz tablet) and 32 and 56 hours (Mtz gel) sampling were 
obtained using sterile syringe and needle. The saliva samples (3mL) were placed into sterile 
tubes (15mL). Immediately after each blood and saliva collection, the samples were 
centrifuged at 3000g for 15min., the plasma and saliva supernatant were placed into 
microtubes (Eppendorf, Hamburg, Germany) and stored at -70 °C until analysis. 
 
Chromatographic Analysis 
Plasmatic and salivary Mtz concentrations were measured by high performance 
liquid chromatography (HPLC), consisting of a Varian pump (Model 9012), a Varian 
detector (ProStar 335 DAD), a Galaxie software and a Varian autosampler (ProStar 410). 
The chromatographic separations were carried out using a Lichrospher column 100 RP18 
(125mm x 4mm x 5µm, Merck, Darnstadt, Germany). A previously adapted and validated 
method (De Cássia-Bergamaschi et al., 2006) was used to analyze Mtz in saliva and 
plasma. 
The saliva samples (500 µL) were submitted to extraction by using 250 µL of a 
protein-precipitation solution (10% perchloric acid and phosphate-citrate buffer, pH 5.4). 
The plasma samples (500 µL) were submitted to extraction by using 250 µL of a protein-
precipitation solution (20% perchloric acid and phosphate-citrate buffer, pH 5.4).  
The samples were vortexed by 30 s, kept at room temperature for 10 min and 
centrifuged (15.000 g) for 15 min at 4°C. Subsequently, 225 µL of pH-adjusting solution 
(sodium hydroxide 1 M and buffer phosphate-citrate, pH= 5.4) was added to supernatant 
(450 µL). 
Tinidazole (20 µL of 100 µg/mL), used as an internal standard, was added to 
samples, which were then eluted with a mobile phase consisting of a 0.01-M aqueous 






1.0 mL/min and the wavelength was set at 320 nm. Retention time was approximately 2 
and 4 minutes for Mtz and tinidazole, respectively. Standard stock solutions from Mtz 
concentrations were diluted in drug-free plasma and saliva (50 µg/mL to 0.01 µg/mL, n=9) 
to achieve the calibration curves. Sample concentrations were calculated by using the 
regression equation of the straight-line y = ax + b, where ‘y’ refers to the peak area ratio, 
‘a’ the slope, ‘b’ the intercept and ‘x’ the unknown drug concentration. 
 
Statistical and Pharmacokinetic analyses 
 Computer software (PK Solutions, Non-compartmental Pharmacokinetics Data 
analysis, Excel Template, 2001, Summit Research Services, Montrose, CO, USA) was used 
to obtain the following parameters: Cmax - the highest concentration observed during the 
48-hour study period; Tmax - the time at which Cmax occurred; AUC0-48 - the area under the 
plasma concentration-time curve from baseline to 48 h; AUC0-∞ - the area under the plasma 
concentration-time curve from baseline to infinity; CL - renal clearance; and VD - 
distribution volume.  
 A power calculation based on the plasmatic and salivary AUC0-48 values (mean and 
standard deviation) showed that 13 subjects had a power of 95%, considering a significance 
level of 5%. Paired Student's t test was used to compare the pharmacokinetic parameters of 
Mtz tablet and the plasmatic and salivary concentrations of Mtz to tablet and gel, at a 
significance level of 5%. Data analysis was carried out using computer Software (BioEstat 
















All volunteers completed the study in good health conditions. Metronidazole (Mtz) 
tablet and gel were well tolerated, since no adverse effects were reported or observed.  
The HPLC was sensitive in quantifying Mtz in plasma and saliva (limit of 
quantification=0.01µg/mL). The method was linear over concentration range 50 µg/ml to 
0.01 µg/ml to saliva and plasma. No interfering peaks were registered at the retention times 
of the drug and internal standard. The assay was validated using seven calibrations curves 
for plasma and saliva that showed good linearity, since the values of linear regression curve 
(R2) were above 0.99.  
Table 1 shows mean values for each pharmacokinetic parameter (Cmax, Tmax, AUC0-
48h, AUC0-∞, VD and CL) concerning plasmatic and (Cmax, Tmax, AUC0-48h and AUC0-∞) 
salivary concentrations involving 13 volunteers, after single oral administration of Mtz. 
Plasma analysis revealed the highest values concerning AUC0-48h and AUC0-∞. 
Mtz was detected in both plasma and saliva 30 minutes after oral administration. 
Plasmatic Mtz concentration values were higher than those observed for saliva at the period 
between 6 and 24 hours after drug tablet administration (p<0.05) (Figure 1A). There were 
no statistically significant differences between salivary and plasmatic concentrations of Mtz 

























(95%)  p 
Cmax  Plasma 11.3 (± 2.06) 9.66 to 12.33 0.367 
(µg/ml) Saliva 11.8 (± 7.9) 7.01 to 16.59  
     
Tmax  Plasma 1.77 (± 0.72) 1.46 to 3.07 0.091 
(h) Saliva 1.50 (± 0.55) 1.01 to 1.68  
     
AUC(0-48) Plasma 197.8 (± 47.88) 178.89 to 227.41 *0.0001 
(µg.h/mL) Saliva 115.1 (± 59.36) 79.20 to 150.95  
     
AUC0-∞ Plasma 210.2 (± 45.69) 187.1 to 239.32 *0.0002 
(µg.h/mL) Saliva 124.2 (± 64.10) 85.42 to 162.90  
     
VD Plasma 625.3 (± 194.65) 511.10 to 798.32 _ 
(mL/Kg) Saliva _   
     
CL Plasma 62.5 (± 15.54) 52.30 to 70.39 _ 
(mL/h) Saliva _    
*statistically significant differences (paired t test, p<0.05), (-) data not calculated 
(Cmax - the highest concentration observed, Tmax - the time at which Cmax; AUC0-48 - the area under the 
concentration-time curve from baseline to 48 h, AUC0-∞ - the area under the concentration-time curve from 









































































































Figure 1. Mean (±SEM) values for plasmatic and salivary concentrations of both 








 The present study used a simple, reproducible and selective chromatography method 
which allows quantification of metronidazole (Mtz) in both plasma and saliva.  This 
method requires 5 minutes for analysis and it uses a low volume of clinical sample (500 
µL). The limit of quantification (0.01 µg/mL) is agreement with previous findings 
indicating the HPLC as a sensitive and reliable method to quantify Mtz in biological fluids 
(Mustofa & Santoso, 1991; Jessa et al., 1996; Spénard et al., 2005; Pahkla et al., 2005).   
 Mtz pharmacokinetic has been investigated in different single oral doses of 125 mg 
(Spénard et al., 2004), 500 mg (Mattila et al., 1983; Mustofa & Santoso, 1991), 1000 mg 
(Sprandel et al., 2004), and 1500 mg (Dilger et al., 2007). One study (Van Oosten et al., 
1986) was related in literature measuring Mtz concentrations in plasma, saliva and gingival 
crevice fluid (GCF), after administration of a single oral dose Mtz (750 mg). However, 
their study included only four subjects, which did not observe fasting. Food is known to 
interfere with the bioavailability of Mtz, mainly in the absorption, reducing the Cmax and 
AUC parameters (Spénard et al., 2005).  
Previous studies using chromatography analyses reported Cmax mean values in 
plasma of 6.9 µg/mL after 400 mg (Jensen & Gugler, 1983), 9.0 µg/mL after 500 mg 
(Matila et al., 1983), 13.6 µg/mL after 750 mg (Van Oosten et al., 1986), 16.3 and 19.6 
mg/L after 1000 mg (Amon et al., 1978; Bergan & Arnold, 1980) and 40.6 mg/L after 2000 
mg (Amon et al., 1978) of Mtz (single oral dose). These results suggest a linear relationship 
between increased antimicrobial dose and increased plasmatic concentration of Mtz. AUC 
values were also found to rise as dosage increased. Daneshmend et al. (1982) observed 
values of 132.2 µg/mL/h for AUC0-24 and Mustofa et al. (1991) of 153.56 µg/mL/h for 
AUC0-48, after oral use of 500 mg Mtz.  
The Tmax values observed in the present study to plasma and saliva were similar to 
those reported by Wood & Monro (1975), Daneshmend et al. (1982) and Jessa et al. (1997), 
using single oral doses of 2000, 400 and 500 mg Mtz, respectively. It is well established 
that Tmax is not influenced by dosage; however, these values were reported varied according 






The high salivary concentration values observed in the present study indicate the 
high Mtz diffusion from blood to saliva. This drug has low molecular weight and it has the 
ability to permeate all tissues and body fluids. Furthermore, Mtz is a weak base with 
minimal plasmatic protein binding (Mustofa et al., 1991). Most drugs, even those highly 
bounded to plasmatic protein, are known no to be bound to salivary proteins (Matin et al., 
1974).  
Although the salivary concentration values, in some periods evaluated in the present 
study, were similar to those obtained for plasma, statistically significant difference was 
observed between AUC0-48h and AUC0-∞. This result occurred mainly due to the higher 
decay of salivary concentration during the elimination phase of drug. Similar results were 
observed by Jessa et al. (1997). However, Mustofa et al. (1991) found similar plasmatic and 
salivary concentrations and suggested replacing plasma with saliva to measure Mtz 
concentration. 
Van Oosten et al. (1986) and Rotzetter et al. (1994) showed that Mtz concentrations 
in GCF were similar to those obtained in saliva and plasma after systemic administration. 
Van Oosten et al. (1986) reported concentrations in GCF varying from 8.7 g/mL to 13.8 
g/mL after a single 750 mg Mtz oral dose. Pahkla et al. (2005) verified a GCF 
concentration approximately 13 g/mL after 500mg Mtz (2 or 3 times/day).  
A single dose of 160 mg Mtz benzoate corresponds to 100 mg Mtz (Mishal & 
Sober, 2005), since the Mtz benzoate is Mtz prodrug. Homeida et al. (1986) related that 
oral bioavailability of Mtz derived from Mtz benzoate is less than 80%. The quantity of 
Mtz benzoate in 3 g of Mtz benzoate gel (15%), which was used in the present study, 
corresponds to 450 mg Mtz benzoate. Considering that the available quantity of Mtz in 
plasma could be at least 20% inferior to that of Mtz benzoate, the initial dose of Mtz in the 
gel formulation tested was approximately 360 mg of Mtz. This lower dose, when compared 
to that used for the tablet, can explain the lower plasmatic and salivary concentrations 
found for Mtz gel between 8 and 48 hours.  
In conclusion, gel formulation had similar Mtz bioavailability in plasma and saliva. 
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Background: Smoking has been widely reported as a significant risk factor for periodontal 
diseases. Metronidazole (Mtz) is a widely prescribed antibiotic in periodontics and the 
effect of smoking on the Mtz pharmacokinetics is not known. The aim of this study was to 
evaluate the effect of cigarette smoking on the bioavailability of Mtz. Methods: 13 
smokers (SM) and 13 nonsmokers (NSM) received a single oral dose of 750 mg Mtz. 
Blood and saliva samples were collected at baseline and 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 and 48 
hours after Mtz administration. Plasmatic and salivary Mtz concentrations were quantified 
by HPLC-UV and its pharmacokinetic parameters, such as the highest concentration (Cmax), 
Cmax time (Tmax), the area under concentration-time curve from zero to infinity (AUC0-∞), 
the area under concentration-time curve from zero to t (AUC0-t), distribution volume (VD) 
and renal clearance (CL), were determined. Non-paired t-test and Mann-Whitney test were 
used to compare the plasmatic and salivary concentrations and the pharmacokinetic 
parameters, respectively (=5%). Results: A significant reduction (p<0.05) in plasmatic 
Mtz concentration was observed in SM at 1 hour (SM=6.6±0.58g/ml and 
NSM=9.3±0.85g/ml), 1.5 hours (SM=8.2±0.59g/ml and NSM=10.7±0.49g/ml) and 2 
hours (SM=8.7±0.74g/ml and NSM=11.2±0.51g/ml). A significant reduction in 
plasmatic Cmax was observed in SM (9.7±2.92g/ml) compared to NSM (11.9±1.95g/ml) 
(p<0.05). No statistically significant difference was observed between SM and NSM 
considering both salivary concentration and salivary pharmacokinetic parameters of Mtz 
(p>0.05). Conclusion: Smoking reduced the Mtz concentration in plasma; however, it had 
no interference with both salivary and plasmatic pharmacokinetic parameters. Further 
studies are needed to assess the clinical significance of these results. 













  Periodontal disease is an infection occurring in the tooth-supporting tissues. The 
cause and progression of periodontal diseases remain rather unclear; however, bacterial 
plaque at the dentogingival junction and in periodontal pockets is known to be the major 
etiologic factor of such diseases.1 
 Previous studies, investigating the relationship between smoking and periodontal 
destruction, have reported smoking as a risk factor for periodontitis.2 Cigarette smokers are 
known to be more susceptible to periodontal diseases 3 and to respond less favorably to the 
periodontal treatment compared to non-smokers.4 They also have a higher risk for 
developing periodontitis which might be due to the length of tobacco use and dose.5  
 It has been suggested that 40% of the cases of chronic periodontitis might be 
attributed to smoking.6 Smoking and tobacco products can alter the subgingival microbiota, 
favoring colonization with periodontal pathogens 7 and the immune-inflamatory host 
response.8  
 Periodontitis treatment includes mechanical removal of supra and subgingival 
microbial biofilm, as well as surgical techniques combined or not with local and systemic 
antimicrobial agents.9 Metronidazol (Mtz) is one of the most commonly used antimicrobial 
agents to treat chronic and aggressive periodontitis, neither of which responds favorably to 
any mechanical treatment.10  
 Mtz is active against a wide variety of anaerobic protozoal parasites and anaerobic 
bacteria.11 Its strict spectrum of activity against anaerobes and its few side effects make it 
suitable for treating periodontitis.12 The treatment for periodontitis by using Mtz has been 
reported as a 5-to-14-day therapy, at doses varying from 250 to 500 mg, two to three times 
a day.13-18  
  Previous studies showed that cigarette smoking interfere with the bioavailability of 
some drugs, such as antineoplasic (erlotinib),19 anti-hipertensive (irbesartan),20 nonsteroidal 
anti-inflammatory (phenylbutazone),21 opioids (codeine and morphine),22,23 neuromuscular 
blocking agents (vecuronium),24 anti-asthmatic (theophylline)24 and antipsychotics 






pharmacokinetic of Mtz was found. Thus, the aim of this study was to evaluate the effect of 
cigarette smoking on the bioavailability of Mtz in both plasma and saliva.  
 
MATERIALS AND METHODS 
Subject Population 
This study was approved by the Ethical Committee of São Leopoldo Mandic Dental 
School, São Paulo, Brazil (#06/456). All participants gave written informed consent and 
were informed of the nature and details of the study. 
This study included twenty-six male subjects, assigned to two groups: G1 –
individuals smoking 12 to 20 (15.5 ± 3.44) cigarettes a day during the study period (n=13) 
and G2 – nonsmokers (n=13). Smokers were 18–24 years old (22 ± 1.67 years), weighed 
60–95 kg (74.6 ± 9.92 kg), were 1.69–1.84 m (1.78 ± 0.046 m) tall and had a body mass 
index of 20.1–27.8 kg/m2 (23.8 ± 2.3 kg/m2). Nonsmokers were 20–24 years old (22.4 ± 
1.35 years), weighed 65–82 kg (73.0 ± 6.82 kg), were 1.68–1.85 m (1.77 ± 0.07 m) tall and 
had body mass index of 20.3–26.1 kg/m2 (23.23 ± 2.07 kg/m2). To be included, smokers 
should have been puffing on at least 12 cigarettes a day for the past 4 years, and 
nonsmokers should never have smoked. All the volunteers were free of cardiac, hepatic, 
renal, pulmonary, neurological, gastrointestinal, and hematological diseases, as well as 
psychiatric disorders, diabetes, glaucoma and allergy to antimicrobials.  
Subjects were instructed to avoid any kind of drug therapy for at least 4 weeks prior 
to study and up to its completion. They were also refrained from xanthine-containing foods 
as well as beverages such as tea, coffee, and cola, 48 hours prior to each dosing and until 
the last blood/saliva sample was collected.27 They were also refrained from alcoholic drinks 
up to a period of 48 hours before and after the last sampling due to risk of drug interaction, 
as Mtz has the ability to produce disulfiram-like reactions in alcohol consumers.28  
Drugs and chemicals 
Mtz tablet (250 mg Flagyl® - Aventis, lot #700277, São Paulo, Brazil) was obtained 
in a drugstore. Mtz and tinidazole (internal standard) were provided by Sigma (St Louis, 






Baker Co. (Phillipsburg, NJ, USA). Sodium hydroxide 1N and perchloric acid (70%, w/v) 
were obtained from Merck (Darmstat, Germany). Distilled water was purified using a 
Millipore system (Milli Q., Millipore). 
Clinical Protocol 
Blood and saliva samples were collected in the ambulatory of São Leopoldo Dental 
School (Campinas, SP, Brazil). The volunteers were instructed to inform of any adverse 
effect they could have during the study. 
After a 12-hour fasting period, subjects received a single oral dose of 750 mg Mtz 
with water (200 mL). Two hours after drug administration, they had a standard breakfast (a 
cup of peach juice and a 50-g loaf of bread with margarine) and were then allowed to 
consume water ad libitium. A complete standardized meal (lunch) was allowed four hours 
after drug administration. Blood (5mL) from antecubital vein via heparinized cannula and 
saliva (not stimulated - 3 mL)  were collected at pre-dose (0), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 
and 48 hours after Mtz oral administration.  
The blood samples were collected by direct venipuncture into sterile tubes 
containing K3EDTA solution. The heparinized saline solution (0.9% NaCl and heparine, 
9.8:0.2) injection (0.2 mL) was flushed into the cannula to prevent blood clotting, after each 
blood sampling. The 24-and-48-hour plasma (5 mL) samples were collected by using sterile 
syringes and needles and placed into sterile vials. Immediately after each blood and saliva 
collection, the samples were centrifuged at 3000 g for 15 min and the supernatant of plasma 
and saliva was placed into microtubes (Eppendorf, Hamburg, Germany) and stored at - 
70°C. 
Chromatographic Analysis 
Plasmatic and salivary Mtz concentrations were measured by high performance 
liquid chromatography (HPLC), which consists of a pump (Varian, Model 9012), a diode 
array detector (Varian, ProStar 335, DAD), software (Varian, Galaxie) and an autosampler 
(Varian, ProStar 410). Chromatographic separations were carried out by using a 
Lichrospher column 100 RP18 (125mm x 4mm x 5µm, Merck). A previously adapted and 
validated method29 was used to analyze salivary and plasmatic Mtz concentrations. 






by using 250 µL of a protein-precipitation solution (10% perchloric acid and phosphate-
citrate buffer, pH 5.4, for saliva and 20% perchloric acid and phosphate-citrate buffer, pH 
5.4, for plasma). The samples were vortexed by 30 s, kept at room temperature for 10 min 
and centrifuged (15.000 g) for 15 min at 4 °C. Subsequently, 225 µL of a pH-adjusting 
solution (sodium hydroxide 1 M and buffer phosphate-citrate, pH= 5.4) was added to the 
supernatant (450 µL). 
Tinidazole (20 µL out of 100 µg/mL), used as an internal standard, was then added 
to the salivary and plasmatic samples, which were then eluted with a mobile phase — a 
0.01-M aqueous solution of sodium monophosphate (pH= 4.7) and acetonitrile (85:15). The 
flow rate was set at 1.0 mL/min, with a wavelength of 320 nm. The retention time was 
approximately 2 and 4 min for Mtz and tinidazole, respectively. 
Standard stock solutions from Mtz concentrations were diluted in drug-free plasma 
and saliva (50µg/mL to 0.01µg/mL, n=9) to obtain the calibration curves. Sample 
concentrations were calculated by using the regression equation of the straight-line (y = ax 
+ b), where ‘y’ refers to the peak area ratio, ‘a’ the slope, ‘b’ the interception and ‘x’ the 
unknown drug concentration. 
Statistical and Pharmacokinetic analyses 
Computer software (PK Solutions, Non-compartmental Pharmacokinetics Data 
analysis, Excel Template, 2001, Summit Research Services, Montrose, CO, USA) was used 
to obtain the following parameters: Cmax - the highest concentration observed during the 
48-hour study period; Tmax - the time at which Cmax occurred; AUC0-t - the area under the 
plasma concentration-time curve from baseline to 24 and 48 h; AUC0-∞ - the area under the 
plasma concentration-time curve from baseline to infinity; CL - renal clearance; and VD - 
distribution volume.  
A power calculation based on Cmax plasmatic values (mean and standard 
deviation) showed that 13 subjects in each group had a power of 70% towards detecting 
difference in pharmacokinetic parameters, at a significance level of 5%. Non-paired t test 
and Mann Whitney test were used to compare concentration and pharmacokinetic 
parameters of Mtz in plasma and saliva, at a significance level of 5%. Data analysis was 







 No significant difference was observed between smokers and nonsmokers, 
regarding their physical characteristics such as age, weight, height and body mass index 
(Non-paired t test, p>0.05). All volunteers completed the study and no adverse effect was 
reported or observed. 
The chromatography method was sensitive in quantifying Mtz in plasma and saliva 
(limit of quantification=0.01µg/mL) and showed good linearity, with the linear regression 
(R2) being higher than 0.99.  
A significant reduction (Non-paired t test, p<0.05) in plasmatic Mtz concentration 
was observed for smokers after 1, 1.5 and 2 hours after Mtz administration. However, no 
significant difference was observed between smokers and nonsmokers, concerning salivary 
Mtz concentration, in any of the periods evaluated (Non-paired t test, p>0.05). The 
plasmatic and salivary concentrations regarding smokers and nonsmokers are shown in 
Figure 1.  
There were no statistically significant differences between smokers and nonsmokers 
concerning all pharmacokinetic parameters, except Cmax, in plasma (Mann-Whitney, 
p<0.05). Table 1 shows mean values for plasmatic pharmacokinetic parameters (Cmax, Tmax, 
ASC0-48, ASC0-inf, VD and CL). No statistically significant difference was observed 
between smokers and nonsmokers concerning pharmacokinetic parameters in saliva (Mann-
Whitney, p>0.05). Table 2 shows mean values obtained for salivary pharmacokinetic 









































Figure 1. Mean values (± SEM) for plasmatic (A) and salivary (B) Mtz 
concentration in smokers and nonsmokers. 
 
 





































































Table 1. Mean values (± SD) for plasmatic pharmacokinetic parameters in smokers 
and nonsmokers. 
 




smoker  9.7 ± 2.92 7.85 to 11.26 Cmax  
(µg/ml) nonsmoker 11.9 ± 1.95 10.69 to 13.05 
0.0230* 
     
smoker  2.9 ± 1.80 1.87 to 4.06 Tmax  
(h) nonsmoker 1.8 ± 0.88 1.22 to 2.30 
0.1910 
     
smoker  194.9 ± 90.10 140.40 to 249.07 AUC (0-48)  
(µg.hr/ml)  nonsmoker 210.9 ± 59.48 174.99 to 246.88 
0.5964 
     
smoker  297.2 ± 228.38 159.54 to 435.46 AUC (0-∞) 
(µg.hr/ml) nonsmoker 290.3 ± 113.98 217.68 to 362.65 
0.4464 
     
smoker  1071.4 ± 561.11 670.04 to 1472.70 VD  
(mL/Kg) nonsmoker 809.7 ± 263.28 621.03 to 998.07 
0.2899 
     
smoker  55.1 ± 33.77 30.86 to 79.13 CL 
(mL/h) nonsmoker 42.0 ± 14.94 31.29 to 52.69 
0.4497 
*statistically significant differences (Mann-Whitney, p<0.05).  
Cmax - the highest concentration detected, Tmax - the time at which Cmax occured; AUC0-48 - 
the area under the concentration-time curve from 0 to 48 h, AUC0-∞ - the area under the 









Table 2. Mean values (± SD) for salivary pharmacokinetic parameters in smokers 
and nonsmokers. 
 




smoker 8.9 ± 4.16 6.32 to 11.34 Cmax  
(µg/ml) nonsmoker 8.3 ± 5.87 4.54 to 12.00 
0.3551 
     
smoker  1.9 ±1.36 1.02 to 0.27 Tmax  
(h) nonsmoker 1.5 ± 0.4 9 1.10 to 1.80 
0.5239 
     
smoker  81.9 ± 24.47 67.13 to 97.68 AUC (0-24) 
(µg.hr/ml)  nonsmoker 76.7 ± 47.29 46.67 to 106.78 
0.7373 
     
smoker  109.9 ± 56.31 75.93 to 143.98 AUC (0-∞) 
(µg.hr/ml) nonsmoker 89.3 ± 24.86 49.72 to 128.90 
0.3907 
Cmax - the highest concentration detected, Tmax - the time at which Cmax occured; AUC0-24 - 
the area under the concentration-time curve from 0 to 24 h, AUC0-∞ - the area under the 
















The possible interaction between smoking and Mtz was investigated since smoking 
is considered a risk factor for periodontal diseases and Mtz seems to be one of the most 
commonly used antibiotics to treat periodontitis. Several studies reported clinical and 
microbiological benefits for the use of Mtz (alone or in combination with amoxicillin) to 
treat chronic 16, 30-35 and aggressive periodontitis 15, 18, 36-40, when used in association with 
mechanical periodontal therapy. 
The method used in the present study to quantify Mtz in plasmatic and saliva 
samples was considered sensitive (limit of quantification=0.01µg/mL) and reliable 
(linearity=0.999).  
Van Oosten et al.41 reported 13.6 µg/mL as Cmax in plasma after a single oral dose 
of 750 mg Mtz. Daneshmend et al.42 observed 132.2 µg/mL/h for AUC0-24, while Mustofa et 
al.43 found 153.56 µg/mL/h for AUC0-48 after a single oral dose of 500 mg Mtz. In the 
present study, AUC0-48 values were observed to be slightly higher than those reported by 
Mustofa et al.,43 suggesting that AUC values might rise as dosage increases. In addition, 
Tmax values previously reported by Wood & Monro44 and Jessa et al.45 (2 h and 1.90 h, 
respectively) were similar to those observed in the present study.  
Mtz MIC values against anaerobic bacteria, known to cause periodontal diseases, 
were found to range from 0.1 to 8 µg/mL.46 The mean Mtz plasmatic concentrations ranged 
from 2.2 to 8.7 µg/mL for smokers and from 2.4 to 11.2 µg/mL for nonsmokers at periods 
between 0.5 and 48 hours. Mtz concentration in saliva (ranging from 1.3 to 6.8 µg/mL for 
smokers and from 1.5 to 7.4 µg/mL for nonsmokers) was in the interval of MIC values 
reported by Leiknes et al.1 in all periods. However, it is necessary to consider that these 
concentrations were observed after a single dose of Mtz. Ralph et al.46 reported higher 
values of Mtz pharmacokinetic parameters and concentrations in plasma for multiple oral 
doses, when compared to single oral doses.  
The number of cigarettes that an individual smokes per day was reported to interfere 
with the pharmacokinetic of drugs in plasma. Wu et al.26 verified that smoking more than 






In the present study, the mean use of 15 cigarettes/day was found to interfere with 
the Mtz concentration in plasma. Therefore, it is possible to suggest that the use of 20 or 
more cigarettes/day, the number consumed by heavy smokers,47 could better evidence a 
possible influence of cigarette smoking on the pharmacokinetic parameters of Mtz in 
plasma and/or saliva.  
Drug interactions associated with cigarette smoking were reported to interfere with 
the hepatic biotransformation of drugs known as substrates of such enzymes as CYP1A1, 
CYP1A2, and CYP2E1, which might be induced by cigarette smoke constituents. 
Polycyclic aromatic hydrocarbons (PAHs) are the main substances known to induce hepatic 
microsomal enzymes and can lead to an increase in the rate of metabolism of certain 
drugs.48 Another metabolic pathway (glucuronide conjugation) can also be induced by 
PAHs.48 Other cigarette smoke substances may also interact with hepatic enzymes but their 
effects appear to be less relevant.49 
Drugs, such as phenylbutazone,21 morphine,22 codeine,23 vecuronium,24 
theophylline,24 clozapine and olanzapine,25 were reported to be metabolized by the enzymes 
mentioned above, and the drug interaction with cigarette smoking resulted in a significant 
reduction in their plasmatic concentrations. It is hypothesized that this same drug 
interaction mechanism might account for the reduction in the Mtz plasmatic concentration 
found in the present study.  
In conclusion, cigarette smoking reduced the Mtz concentration in plasma; however, it had 
no interference with both salivary and plasmatic pharmacokinetic parameters. Further 
studies are needed to assess the clinical significance of these results. 
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3. CONSIDERAÇÕES GERAIS 
A literatura apresenta muitos estudos clínicos com o uso de antimicrobianos 
associados ao tratamento periodontal mecânico. No entanto, os achados apresentam 
resultados divergentes quanto à efetiva contribuição desses agentes ao tratamento 
periodontal. Segundo Haffajee et al. (2003), os dados da literatura são suficientes para 
sugerir que os antimicrobianos auxiliam no tratamento das periodontites, a dificuldade é 
estabelecer um protocolo de uso.  
O presente estudo pretendeu verificar se o uso do gel de metronidazol (Mtz) (15%) 
em moldeira traria benefício clínico adicional quando associado ao procedimento mecânico 
em fumantes com periodontite crônica. Este tipo de aplicação poderia promover a reposição 
do antimicrobiano “perdido” para dentro da bolsa periodontal, uma vez que o alto fluxo do 
fluído gengival dificulta sua permanência neste local. Além disso, a alta concentração 
salivar do Mtz durante o uso do gel ajudaria a eliminar microrganismos presentes na saliva. 
 Entretanto, no presente estudo, não foi observado benefício clínico adicional ao 
tratamento periodontal com o uso do Mtz nas condições avaliadas. Na tentativa de explicar 
estes resultados, foi observado que o uso de Mtz foi mais efetivo em bolsas profundas que 
em rasas (Loesche et al., 2002; Feres et al., 2001; Carvalho et al., 2004). Também foi 
sugerido que a dose usada ou a duração do tratamento são fatores relevantes para avaliar a 
eficácia antimicrobiana deste agente no tratamento periodontal (Van Winkelhoff et al., 
1999; Herrera et al., 2008). Além disso, o fato de fumantes ter uma resposta menos 
favorável à terapia periodontal comparada à não-fumantes (Van der Velden et al., 2003; 
Labriola et al., 2005; Palmer et al., 2005) poderia interferir nos resultados observados.  
No segundo estudo foi observada uma maior concentração plasmática e salivar com 
o uso do comprimido comparado ao gel de Mtz nos períodos de 8 a 48 horas; no entanto, 
ambas as formulações não demonstraram benefício clínico adicional ao procedimento 
periodontal sozinho, podendo-se sugerir que um aumento na concentração do gel e na 
dosagem do comprimido pudesse proporcionar esta melhora ao tratamento periodontal. 
Não foi possível determinar as concentrações de Mtz na saliva durante o uso do gel 






concentrações salivares tenham sido maiores durante o uso do gel comparadas àquelas 
observadas nos períodos de colheita das amostras (8 a 48 horas após a aplicação do gel).  
Deve-se levar em consideração à crescente preocupação com a prescrição de 
antimicrobianos no que se refere aos efeitos adversos e principalmente ao aumento da 
resistência bacteriana (Mombelli, 2005; Haffajee et al., 2006), o que restringe o uso destas 
substâncias a certas condições periodontais definidas (doença refratária ou severa) e a 
determinados pacientes (como os fumantes) na qual a doença pode requerer um tratamento 
mais agressivo (Herrera et al., 2002; Herrera et al., 2008). 
 No terceiro estudo foi observada uma diminuição na concentração plasmática do 
Mtz que em contrapartida resultou apenas em diminuição do parâmetro Cmax em plasma. 
Estes achados merecem melhor investigação, uma vez que o estudo foi realizado com o uso 
de dose oral única e os pacientes foram selecionados com base num mesmo padrão de 
consumo de cigarro. É possível que haja uma alteração mais significativa na 
farmacocinética do Mtz, quando modificados os parâmetros tempo de uso do 
antimicrobiano e consumo de cigarros. Embora exista a necessidade de melhor 
investigação, há evidências que comprovam diminuição na biodisponibilidade plasmática 
do Mtz em fumantes e, somando este achado aos resultados obtidos com o estudo clínico de 
pacientes fumantes com doença periodontal; pode-se concluir, dentro das limitações do 
presente estudo, que o Mtz não mostrou vantagem clínica adicional ao tratamento da 
periodontite crônica em fumantes, não havendo necessidade do seu uso associado ao 












4. CONCLUSÕES  
 
 As conclusões do presente estudo foram: 
 
1) O metronidazol (Mtz) nas formulações gel e comprimido associados ao debridamento 
periodontal não demonstraram melhora clínica adicional, não havendo vantagem no uso 
destas formulações, dentro das condições avaliadas no presente estudo; 
2) As concentrações plasmáticas e salivares obtidas com a formulação gel de Mtz foram 
similares; 
3) Alguns dos parâmetros farmacocinéticos do Mtz em comprimido foram maiores no 
plasma que na saliva;  
4) O cigarro reduziu a concentração plasmática do Mtz no plasma, mas não inteferiu nos 


















1. Anwar H, Strap JL, Costerton JW. Establishment of aging biofilms: possible 
mechanism of bacterial resistance to antimicrobial therapy. Antimicrob Agents 
Chemother. 1992 Jul;36(7):1347-51. Review.  
2. Carvalho LH, D'Avila GB, Leão A, Gonçalves C, Haffajee AD, Socransky SS, Feres 
M. Scaling and root planing, systemic metronidazole and professional plaque removal in 
the treatment of chronic periodontitis in a Brazilian population II: microbiological results. 
J Clin Periodontol. 2005 Apr;32(4):406-11.  
3. Carvalho LH, D'Avila GB, Leão A, Haffajee AD, Socransky SS, Feres M. Scaling and 
root planing, systemic metronidazole and professional plaque removal in the treatment of 
chronic periodontitis in a Brazilian population. I. clinical results. J Clin Periodontol. 2004 
Dec;31(12):1070-6. 
4. Darby IB, Mooney J, Kinane DF. Changes in subgingival microflora and humoral 
immune response following periodontal therapy. J Clin Periodontol. 2001 
Aug;28(8):796-805. 
5. Drisko CH. The use of locally delivered doxycycline in the treatment of periodontitis. 
Clinical results. J Clin Periodontol. 1998 Nov;25(11 Pt 2):947-52; discussion 978-9. 
6. Elter JR, Lawrence HP, Offenbacher S, Beck JD. Meta-analysis of the effect of 
systemic metronidazole as an adjunct to scaling and root planing for adult periodontitis. J 
Periodontol Res 1997;32:487–496. 
7. Feres M, Haffajee AD, Allard K, Som S, Socransky SS. Change in subgingival 
microbial profiles in adult periodontitis subjects receiving either systemically-
administered amoxicillin or metronidazole. J Clin Periodontol. 2001 Jul;28(7):597-609 
8. Greenstein G. Nonsurgical periodontal therapy in 2000: a literature review. J Am Dent 
Assoc. 2000 Nov;131(11):1580-92. Review 
9. Griffiths GS, Smart GJ, Bulman JS, Weiss G, Shrowder J, Newman HN. Comparison 
of clinical outcomes following treatment of chronic adult periodontitis with subgingival 
                                                 
1 De acordo com a norma da UNICAMP/FOP, baseadas na norma do Internacional Commitee of Medical Journal Editors 






scaling or subgingival scaling plus metronidazole gel. J Clin Periodontol. 2000 
Dec;27(12):910-7. 
10.  Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC. What do we really know 
about antibiotic pharmacodynamics? Pharmacotherapy 2001;21(11s):302s-318s.  
11.  Haffajee AD, Patel M, Socransky SS. Microbiological changes associated with four 
different periodontal therapies for the treatment of chronic periodontitis. Oral Microbiol 
Immunol. 2008 Apr;23(2):148-57. 
12. Haffajee AD. Systemic antibiotics: to use or not to use in the treatment of periodontal 
infections. That is the question. J Clin Periodontol. 2006 May;33(5):359-61.  
13. Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-infective periodontal 
therapy. A systematic review. Ann Periodontol. 2003 Dec;8(1):115-81.  
14. Herrera D, Alonso B, León R, Roldán S, Sanz M. Antimicrobial therapy in 
periodontitis: the use of systemic antimicrobials against the subgingival biofilm. J Clin 
Periodontol. 2008 Sep;35(8 Suppl):45-66.  
15. Herrera D, Sanz M, Jepsen S, Needleman I, Roldán S. A systematic review on the 
effect of systemic antimicrobials as an adjunct to scaling and root planing in periodontitis 
patients. J Clin Periodontol. 2002;29 Suppl 3:136-59. 
16. Heasman L, Stacey F, Preshaw PM, McCracken GI, Hepburn S, Heasman PA. The 
effect of smoking on periodontal treatment response: a review of clinical evidence. J Clin 
Periodontol. 2006 Apr;33(4):241-53.  
17. Hitzig C, Charbit Y, Bitton C, Fosse T, Teboul M, Hannoun L, Varonne R. Topical 
metronidazole as an adjunct to subgingival debridement in the treatment of chronic 
periodontitis. J Clin Periodontol. 1994 Feb;21(2):146-51. 
18. Jansson H. Studies on periodontitis and analyses of individuals at risk for periodontal 
diseases. Swed Dent J Suppl. 2006;(180):5-49. 
19. Jervøe-Storm PM, AlAhdab H, Semaan E, Fimmers R, Jepsen S. Microbiological 
outcomes of quadrant versus full-mouth root planing as monitored by real-time PCR. J 
Clin Periodontol. 2007 Feb;34(2):156-63.  
20. Johnson GK, Guthmiller JM. The impact of cigarette smoking on periodontal disease 






21. Jorgensen MG, Aalam A, Slots J. Periodontal antimicrobials--finding the right 
solutions. Int Dent J. 2005 Feb;55(1):3-12. 
22. Jorgensen MG, Slots J. Practical antimicrobial periodontal therapy. Compend Contin 
Educ Dent  2000 Feb;21(2):111-24. 
23. Koshy G, Kawashima Y, Kiji M, Nitta H, Umeda M, Nagasawa T, Ishikawa I. Effects 
of single-visit full-mouth ultrasonic debridement versus quadrant-wise ultrasonic 
debridement. J Clin Periodontol. 2005 Jul;32(7):734-43. 
24. Kroon LA. Drug interactions with smoking. Am J Health-Syst Pharm.; 64:1917-21, 
2000.  
25. Labriola A, Needleman I, Moles DR. Systematic review of the effect of smoking on 
nonsurgical periodontal therapy. Periodontol 2000. 2005;37:124-37.  
26. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical                                     
pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin 
Pharmacokinet  1992 Nov;23:328-364. 
27. Leiknes T, Leknes KN, Böe OE, Skavland RJ, Lie T. Topical use of a metronidazole 
gel in the treatment of sites with symptoms of recurring chronic inflammation. J 
Periodontol. 2007 Aug;78(8):1538-44. 
28. Liébana J, Castillo AM, Alvarez M. Periodontal diseases: microbiological 
considerations. Med Oral Patol Oral Cir Bucal. 2004;9 Suppl:82-91; 75-82.  
29. Loesche WJ, Giordano JR, Soehren S, Kaciroti N. The nonsurgical treatment of 
patients with periodontal disease: results of five years. J Am Dent Assoc. 2002 
Mar;133(3):311-20. 
30. López NJ, Gamonal JA, Martinez B. Repeated metronidazole and amoxicillin 
treatment of periodontitis. A follow-up study. J Periodontol. 2000 Jan;71(1):79-89. 
31. López NJ, Gamonal JA. Effects of metronidazole plus amoxicillin in progressive 
untreated adult periodontitis: results of a single 1-week course after 2 and 4 months. J 
Periodontol. 1998 Nov;69(11):1291-8. 
32. Moeintaghavi A, Talebi-ardakani MR, Haerian-ardakani A, Zandi H, Taghipour S, 






metronidazole with scaling and root planing: a randomized, placebo controlled clinical 
trial. J Contemp Dent Pract. 2007 Jul 1;8(5):51-9.  
33. Mombelli A. Antimicrobial profiles of periodontal pathogens and systemic 
antimicrobial therapy. J Clin Periodontol. 2005 Aug;32(8):891-2.  
34. Mongardini C, van Steenberghe D, Dekeyser C, Quirynen M. One stage full- versus 
partial-mouth disinfection in the treatment of chronic adult or generalized early-onset 
periodontitis. I. Long-term clinical observations. J Periodontol. 1999 Jun;70(6):632-45. 
35. Mullally B, Irwin C, Ziada H, Allen E, Byrne PJ. Periodontics: 3. Non-surgical 
periodontal therapy in general dental practice. Dent Update. 2008 Jul-Aug;34(6):326-8, 
330-2, 335-6. Review / 2007 
36. Novak MJ, Dawson DR 3rd, Magnusson I, Karpinia K, Polson A, Polson A, Ryan 
ME, Ciancio S, Drisko CH, Kinane D, Powala C, Bradshaw M. Combining host 
modulation and topical antimicrobial therapy in the management of moderate to severe 
periodontitis: a randomized multicenter trial. J Periodontol. 2008 Jan;79(1):33-41. 
37. Pavia M, Nobile CG, Bianco A, Angelillo IF Meta-analysis of local metronidazole in 
the treatment of chronic periodontitis. J Periodontol. 2004 Jun;75(6):830-8.  
38. Palmer RM, Wilson RF, Hasan AS, Scott DA. Mechanisms of action of 
environmental factors--tobacco smoking. J Clin Periodontol. 2005;32 Suppl 6:180-95.  
39. Quirynen M, Bollen CM, Vandekerckhove BN, Dekeyser C, Papaioannou W, Eyssen 
H Full- vs. partial-mouth disinfection in the treatment of periodontal infections: short-
term clinical and microbiological observations. J Dent Res. 1995 Aug;74(8):1459-67.  
40. Quirynen M, De Soete M, Dierickx K, van Steenberghe D. The intra-oral 
translocation of periodontopathogens jeopardises the outcome of periodontal therapy. A 
review of the literature. J Clin Periodontol. 2001 Jun;28(6):499-507. 
41. Quirynen M, Mongardini C, Pauwels M, Bollen CM, Van Eldere J, van Steenberghe 
D. One stage full- versus partial-mouth disinfection in the treatment of chronic adult or 
generalized early-onset periodontitis. II. Long-term impact on microbial load. J 
Periodontol. 1999 Jun;70(6):646-56. 
42. Rosa GM, Lucas GQ, Lucas ON. Cigarette smoking and alveolar bone in young 






43. Rudney JD, Chen R, Sedgewick GJ. Intracellular Actinobacillus 
actinomycetemcomitans and Porphyromonas gingivalis in buccal epithelial cells collected 
from human subjects. Infect Immun. 2001 Apr;69(4):2700-7. 
44. Salvi GE, Lawrence HP, Offenbacher S, Beck JD. Influence of risk factors on the 
pathogenesis of periodontitis. Periodontol 2000. 1997 Jun;14:173-201. Review.  
45. Slots J, Feik D, Rams TE. In vitro antimicrobial sensitivity of enteric rods and 
pseudomonads from advanced adult periodontitis. Oral Microbiol Immunol. 1990 
Oct;5(5):298-301. 
46. Smart GJ, Wilson M, Davies EH, Kieser JB. The assessment of ultrasonic root 
surface debridement by determination of residual endotoxin levels. J Clin Periodontol. 
1990 Mar;17(3):174-8. 
47. Socransky SS, Haffajee AD. The nature of periodontal diseases. Ann Periodontol. 
1997 Mar;2(1):3-10.. 
48. Spénard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M. Influence of 
omeprazole on bioavailability of bismuth following administration of a triple capsule of 
bismuth biskalcitrate, metronidazole, and tetracycline. J Clin Pharmacol. 2004 
Jun;44(6):640-5. 
49. Sprandel KA, Schriever CA, Pendland SL, Quinn JP, Gotfried MH, Hackett S, 
Graham MB, Danziger LH, Rodvold KA. Pharmacokinetics and pharmacodynamics of 
intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy 
adult subjects. Antimicrob Agents Chemother. 2004 Dec;48(12):4597-605. 
50. Sweeney BP, Grayling M. Smoking and anaesthesia: the pharmacological 
implications. Anaesthesia. 2009 Feb;64(2):179-86. 
51. Thomson WM, Broadbent JM, Welch D, Beck JD, Poulton R. Cigarette smoking and 
periodontal disease among 32-year-olds: a prospective study of a representative birth 
cohort. J Clin Periodontol. 2007 Oct;34(10):828-34.  
52. Van der Velden U, Varoufaki A, Hutter JW, Xu L, Timmerman MF, Van Winkelhoff 
AJ, Loos BG. Effect of smoking and periodontal treatment on the subgingival microflora. 






53. Van Winkelhoff AJ, Winkel EG, Vandenbroucke-Grauls CM. On the dosage of 
antibiotics in clinical trials. J Clin Periodontol. 1999 Nov;26(11):764-6. 
54. Waerhaug J. Healing of the dento-epithelial junction following subgingival plaque 
control. II: As observed on extracted teeth. J Periodontol. 1978 Mar;49(3):119-34.  
55. Wennström JL, Newman HN, MacNeill SR, Killoy WJ, Griffiths GS, Gillam DG, 
Krok L, Needleman IG, Weiss G, Garrett S. Utilisation of locally delivered doxycycline 
in non-surgical treatment of chronic periodontitis. A comparative multi-centre trial of 2 
treatment approaches. J Clin Periodontol. 2001 Aug;28(8):753-61.  
56. Wennström JL, Tomasi C, Bertelle A, Dellasega E. Full-mouth ultrasonic 
debridement versus quadrant scaling and root planing as an initial approach in the 
treatment of chronic periodontitis. J Clin Periodontol. 2005 Aug;32(8):851-9. 
57. Wong MY, Lu CL, Liu CM, Hou LT. Microbiological response of localized sites 
with recurrent periodontitis in maintenance patients treated with tetracycline fibers. J 
Periodontol 1999 Aug;70(8):861-8. 
58. Zanatta GM, Bittencourt S, Nociti FH Jr, Sallum EA, Sallum AW, Casati MZ. 
Periodontal debridement with povidone-iodine in periodontal treatment: short-term 
clinical and biochemical observations. J Periodontol. 2006 Mar;77(3):498-505. 
59. Zhang S, Liu P, Jiang S, Hong X, Xing H, Xu X. Association of cigarette smoking 
with steady-state plasma concentration of irbesartan in male Chinese with hypertension. 
Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):173-8. 
 
 
 
 
 
 
Anexos 
 
 74 
 
ANEXO 1 
 
Anexos 
 
 75 
 
 
 
Anexos 
 
 76 
 
 
 
Anexos 
 
 77 
 
 
 
Anexos 
 
 78 
 
 
 
 
 
 
Anexos 
 
 79 
 
ANEXO 3 
 
 
 
